

- protease homolog secreted by adipose tissue and sciatic nerve. *Science*. 1987;237(4813):402–405. [PubMed: 3299705]
3. Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. *Semin. Cell Dev. Biol.* 1999;10(1):31–41. [PubMed: 10355026]
 4. Saleh J, Al-Wardy N, Farhan H, Al-Khanbashi M, Cianflone K. Acylation stimulating protein: a female lipogenic factor? *Obes. Rev.* 2011;12(6):440–448. [PubMed: 21348923]
 5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature*. 1994;372(6505):425–432. [PubMed: 7984236]
 6. Chlouverakis C. Insulin resistance of parabiotic obese-hyperglycemic mice (obob). *Horm. Metab. Res.* 1972;4(3):143–148. [PubMed: 5044222]
 7. Cava A, La, Matarese G. The weight of leptin in immunity. *Nat. Rev. Immunol.* 2004;4(5):371–379. [PubMed: 15122202]
 8. Carobbio S, Pellegrinelli V, Vidal-Puig A. Adipose tissue function and expandability as determinants of lipotoxicity and the metabolic syndrome. In: *Obesity and Lipotoxicity*. Springer, Cham; 2017:161–196. [PubMed: 28585199]
 9. Cancers Associated with Overweight and Obesity Make up 40 percent of Cancers Diagnosed in the United States | CDC Online Newsroom | CDC. Available at: <https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html>. Accessed January 21, 2019.
 10. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS data brief, no 288. Hyattsville, MD: National Center for Health Statistics; 2017. Available at: <https://www.cdc.gov/nchs/products/databriefs/db288.htm>. Accessed February 27, 2019. [PubMed: 29155689]
 11. Hruby A, Hu FB. The epidemiology of obesity: A big picture. *Pharmacoeconomics*. 2015;33(7):673–689. [PMC free article: PMC4859313] [PubMed: 25471927]
 12. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. *Am. J. Physiol. Metab.* 2007;293(2):E444–E452. [PubMed: 17473055]
 13. Zingaretti MC, Crosta F, Vitali A, Guerrieri M, Frontini A, Cannon B, Nedergaard J, Cinti S. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. *FASEB J.* 2009;23(9):3113–3120. [PubMed: 19417078]
 14. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng Y-H, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. *N. Engl. J. Med.* 2009;360(15):1509–1517. [PMC free article: PMC2859951] [PubMed: 19357406]
 15. Au-Yong ITH, Thorn N, Ganatra R, Perkins AC, Symonds ME. Brown adipose tissue and seasonal variation in humans. *Diabetes*. 2009;58(11):2583–7. [PMC free article: PMC2768171] [PubMed: 19696186]
 16. Hibi M, Oishi S, Matsushita M, Yoneshiro T, Yamaguchi T, Usui C, Yasunaga K, Katsuragi Y, Kubota K, Tanaka S, Saito M. Brown adipose tissue is involved in diet-induced thermogenesis and whole-body fat utilization in healthy humans. *Int. J. Obes. (Lond)*. 2016;40(11):1655–1661. [PMC free article: PMC5116053] [PubMed: 27430878]
 17. de Sá PM, Richard AJ, Hang H, Stephens JM. Transcriptional regulation of adipogenesis. In: *Comprehensive Physiology*. Vol 7. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2017:635–674. [PubMed: 28333384]
 18. Cinti S. The adipose organ at a glance. *Dis. Model. Mech.* 2012;5(5):588–594. [PMC free article: PMC3424455] [PubMed: 22915020]
 19. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang A-H, Khandekar M, Virtanen KA, Nuutila P, Schaart G, Huang K, Tu H, van Marken Lichtenbelt WD, Hoeks J, Enerbäck S, Schrauwen P, Spiegelman BM. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell*. 2012;150(2):366–376. [PMC free article: PMC3402601] [PubMed: 22796012]
 20. Barbatelli G, Murano I, Madsen L, Hao Q, Jimenez M, Kristiansen K, Giacobino JP, De Matteis R, Cinti S. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. *Am. J. Physiol. Metab.* 2010;298(6):E1244–E1253. [PubMed: 20354155]
 21. Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. *Am. J. Physiol. Physiol.* 2000;279(3):C670–C681. [PubMed: 10942717]

22. Young P, Arch JRS, Ashwell M. Brown adipose tissue in the parametrial fat pad of the mouse. *FEBS Lett.* 1984;167(1):10–14. [PubMed: 6698197]
23. Loncar D, Afzelius BA, Cannon B. Epididymal white adipose tissue after cold stress in rats. I. Nonmitochondrial changes. *J. Ultrastruct. Mol. Struct. Res.* 1988;101(2–3):109–122. [PubMed: 3268608]
24. Wang S, Pan M-H, Hung W-L, Tung Y-C, Ho C-T. From white to beige adipocytes: therapeutic potential of dietary molecules against obesity and their molecular mechanisms. *Food Funct.* 2019;10:1263–1279. [PubMed: 30735224]
25. Mika A, Macaluso F, Barone R, Di Felice V, Sledzinski T. Effect of exercise on fatty acid metabolism and adipokine secretion in adipose tissue. *Front. Physiol.* 2019;10(26):1–7. [PMC free article: PMC6360148] [PubMed: 30745881]
26. Reynés B, Palou M, Rodríguez AM, Palou A. Regulation of adaptive thermogenesis and browning by prebiotics and postbiotics. *Front. Physiol.* 2018;9:1–15. [PMC free article: PMC6335971] [PubMed: 30687123]
27. Kaisanlahti A, Glumoff T. Browning of white fat: agents and implications for beige adipose tissue to type 2 diabetes. *J. Physiol. Biochem.* 2019;75(1):1–10. [PMC free article: PMC6513802] [PubMed: 30506389]
28. Ikeda K, Maretich P, Kajimura S. The common and distinct features of brown and beige adipocytes. *Trends Endocrinol. Metab.* 2018;29(3):191–200. [PMC free article: PMC5826798] [PubMed: 29366777]
29. Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S. MECHANISMS IN ENDOCRINOLOGY: White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. *Eur. J. Endocrinol.* 2014;170(5):R159–R171. [PubMed: 24468979]
30. Cinti S. Pink Adipocytes. *Trends Endocrinol. Metab.* 2018;1–16. [PubMed: 30017740]
31. Apostoli AJ, Skelhorne-Gross GEA, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, SenGupta SK, Nicol CJ B. Loss of PPAR γ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. *Int. J. Cancer.* 2014;134(5):1055–1066. [PMC free article: PMC4233966] [PubMed: 23934545]
32. Chu M, Sampath H, Cahana DY, Kahl CA, Somwar R, Cornea A, Roberts CT, Varlamov O. Spatiotemporal dynamics of triglyceride storage in unilocular adipocytes. Gruenberg JE, ed. *Mol. Biol. Cell* 2014;25(25):4096–4105. [PMC free article: PMC4263452] [PubMed: 25298400]
33. Kersten S. Physiological regulation of lipoprotein lipase. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids.* 2014;1841(7):919–933. [PubMed: 24721265]
34. Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. *Br. J. Nutr.* 1998;80(6):495–502. [PubMed: 10211047]
35. Frayn K. Adipose tissue as a buffer for daily lipid flux. *Diabetologia.* 2002;45(9):1201–1210. [PubMed: 12242452]
36. Luo L, Liu M. Adipose tissue in control of metabolism. *J. Endocrinol.* 2016;231(3):R77–R99. [PMC free article: PMC7928204] [PubMed: 27935822]
37. Harris CA, Haas JT, Streeper RS, Stone SJ, Kumari M, Yang K, Han X, Brownell N, Gross RW, Zechner R, Farese R V Jr. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. *J. Lipid Res.* 2011;52(4):657–667. [PMC free article: PMC3284159] [PubMed: 21317108]
38. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese R V. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. *Nat. Genet.* 2000;25(1):87–90. [PubMed: 10802663]
39. Song Z, Xiaoli AM, Yang F. Regulation and metabolic significance of de novo lipogenesis in adipose tissues. *Nutrients.* 2018;10(1383):1–22. [PMC free article: PMC6213738] [PubMed: 30274245]
40. Swierczynski J, Goyke E, Wach L, Pankiewicz A, Kochan Z, Adamonis W, Sledzinski Z, Aleksandrowicz Z. Comparative study of the lipogenic potential of human and rat adipose tissue. *Metabolism.* 2000;49(5):594–599. [PubMed: 10831168]
41. Letexier D, Pinteux C, Large V, Fréring V, Beylot M. Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. *J. Lipid Res.* 2003;44(11):2127–2134. [PubMed: 12897191]
42. Aarsland A, Chinkes D, Wolfe RR. Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding. *Am. J. Clin. Nutr.* 1997;65(6):1774–1782. [PubMed: 9174472]
43. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress. *World J. Gastroenterol.* 2009;15(33):4137. [PMC free article: PMC2738809] [PubMed: 19725147]

44. Crewe C, Zhu Y, Paschoal VA, Joffin N, Ghaben AL, Gordillo R, Oh DY, Liang G, Horton JD, Scherer PE. SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1. *JCI Insight*. 2019;4(15) [PMC free article: PMC6693888] [PubMed: 31310592] [CrossRef]
45. Herman MA, Peroni OD, Villoria J, Schön MR, Abumrad NA, Blüher M, Klein S, Kahn BB. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. *Nature*. 2012;484(7394):333–338. [PMC free article: PMC3341994] [PubMed: 22466288]
46. Vijayakumar A, Aryal P, Wen J, Syed I, Vazirani RP, Moraes-Vieira PM, Camporez JP, Gallop MR, Perry RJ, Peroni OD, Shulman GI, Saghatelian A, McGraw TE, Kahn BB. Absence of carbohydrate response element binding protein in adipocytes causes systemic insulin resistance and impairs glucose transport. *Cell Rep*. 2017;21(4):1021–1035. [PMC free article: PMC5771491] [PubMed: 29069585]
47. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. *J. Clin. Invest.* 1997;100(8):2115–2124. [PMC free article: PMC508404] [PubMed: 9329978]
48. Lodhi IJ, Wei X, Semenkovich CF. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. *Trends Endocrinol. Metab.* 2011;22(1):1–8. [PMC free article: PMC3011046] [PubMed: 20889351]
49. Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. *J. Intern. Med.* 2016;280(5):465–475. [PMC free article: PMC5218584] [PubMed: 27699898]
50. Zhou P, Santoro A, Peroni OD, Nelson AT, Saghatelian A, Siegel D, Kahn BB. PAHSAs enhance hepatic and systemic insulin sensitivity through direct and indirect mechanisms. *J. Clin. Invest.* 2019;129(10):4138–4150. [PMC free article: PMC6763232] [PubMed: 31449056]
51. Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, Homan EA, Patel RT, Lee J, Chen S, Peroni OD, Dhaneshwar AS, Hammarstedt A, Smith U, McGraw TE, Saghatelian A, Kahn BB. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. *Cell*. 2014;159(2):318–32. [PMC free article: PMC4260972] [PubMed: 25303528]
52. Eissing L, Scherer T, Tödter K, Knippschild U, Greve JW, Buurman WA, Pinnschmidt HO, Rensen SS, Wolf AM, Bartelt A, Heeren J, Buettner C, Scheja L. De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health. *Nat. Commun.* 2013;4:1528. [PMC free article: PMC3740744] [PubMed: 23443556]
53. Bruss MD, Khambatta CF, Ruby MA, Aggarwal I, Hellerstein MK. Calorie restriction increases fatty acid synthesis and whole body fat oxidation rates. *Am. J. Physiol. Metab.* 2010;298(1):E108–E116. [PMC free article: PMC4056782] [PubMed: 19887594]
54. Mottillo EP, Balasubramanian P, Lee Y-H, Weng C, Kershaw EE, Granneman JG. Coupling of lipolysis and de novo lipogenesis in brown, beige, and white adipose tissues during chronic β3-adrenergic receptor activation. *J. Lipid Res.* 2014;55(11):2276–2286. [PMC free article: PMC4617130] [PubMed: 25193997]
55. Braun K, Oeckl J, Westermeier J, Li Y, Klingenspor M. Non-adrenergic control of lipolysis and thermogenesis in adipose tissues. *J. Exp. Biol.* 2018;221:1–14. [PubMed: 29514884]
56. Kuriyama H, Shimomura I, Kishida K, Kondo H, Furuyama N, Nishizawa H, Maeda N, Matsuda M, Nagaretani H, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. *Diabetes*. 2002;51(10):2915–2921. [PubMed: 12351427]
57. Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis. *Biochim. Biophys. acta. Mol. cell Biol. lipids*. 2017;1862 10 Pt B:1221–1232. [PMC free article: PMC5595658] [PubMed: 28754637]
58. Nielsen TS, Jessen N, Jorgensen JOL, Moller N, Lund S. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. *J. Mol. Endocrinol.* 2014;52(3):R199–R222. [PubMed: 24577718]
59. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. *J. Biol. Chem.* 1991;266(17):11341–11346. [PubMed: 2040638]
60. Strålfors P, Björgell P, Belfrage P. Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. *Proc.*

- Natl. Acad. Sci. U. S. A. 1984;81(11):3317–3321. [PMC free article: PMC345498] [PubMed: 6374655]
61. Garton AJ, Campbell DG, Cohen P, Yeaman SJ. Primary structure of the site on bovine hormone-sensitive lipase phosphorylated by cyclic AMP-dependent protein kinase. FEBS Lett. 1988;229(1):68–72. [PubMed: 3345839]
62. Anthonsen MW, Rönnstrand L, Wernstedt C, Degerman E, Holm C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J. Biol. Chem. 1998;273(1):215–221. [PubMed: 9417067]
63. Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, Kienesberger P, Strauss JG, Gorkiewicz G, Zechner R. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab. 2006;3(5):309–319. [PubMed: 16679289]
64. Granneman JG, Moore H-PH, Krishnamoorthy R, Rathod M. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J. Biol. Chem. 2009;284(50):34538–34544. [PMC free article: PMC2787315] [PubMed: 19850935]
65. Jensen MD. Gender differences in regional fatty acid metabolism before and after meal ingestion. J. Clin. Invest. 1995;96(5):2297–303. [PMC free article: PMC185880] [PubMed: 7593616]
66. Gjedsted J, Gormsen LC, Nielsen S, Schmitz O, Djurhuus CB, Keiding S, Ørskov H, Tønnesen E, Møller N. Effects of a 3-day fast on regional lipid and glucose metabolism in human skeletal muscle and adipose tissue. Acta Physiol. 2007;191(3):205–216. [PubMed: 17784905]
67. Moro C, Pillard F, de Glisezinski I, Crampes F, Thalamas C, Harant I, Marques M-A, Lafontan M, Berlan M. Sex differences in lipolysis-regulating mechanisms in overweight subjects: effect of exercise intensity*. Obesity. 2007;15(9):2245–2255. [PubMed: 17890493]
68. Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016;125:259–266. [PubMed: 26542285]
69. Czech MP. Mechanisms of insulin resistance related to white, beige and brown adipocytes. Mol. Metab. 2020. in press. doi:<https://doi.org/>. [PMC free article: PMC6997501] [PubMed: 32180558] [CrossRef]
70. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 2017;23(7):804–814. [PMC free article: PMC6048953] [PubMed: 28697184]
71. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, Charpentier G, Auclair M, Delépine M, Barroso I, Semple RK, Lathrop M, Lascols O, Capeau J, O’Rahilly S, Magré J, Savage DB, Vigouroux C. Perilipin deficiency and autosomal dominant partial lipodystrophy. N. Engl. J. Med. 2011;364(8):740–8. [PMC free article: PMC3773916] [PubMed: 21345103]
72. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, Hyden CSS, Bottomley W, Vigouroux C, Magré J, Raymond-Barker P, Murgatroyd PR, Chawla A, Skepper JN, Chatterjee VK, Suliman S, Patch A-M, Agarwal AK, Garg A, Barroso I, Cinti S, Czech MP, Argente J, O’Rahilly S, Savage DB. LD Screening Consortium LS. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEc. EMBO Mol. Med. 2009;1(5):280–7. [PMC free article: PMC2891108] [PubMed: 20049731]
73. Zhou L, Park S-Y, Xu L, Xia X, Ye J, Su L, Jeong K-H, Hur JH, Oh H, Tamori Y, Zingaretti CM, Cinti S, Argente J, Yu M, Wu L, Ju S, Guan F, Yang H, Choi CS, Savage DB, Li P. Insulin resistance and white adipose tissue inflammation are uncoupled in energetically challenged Fsp27-deficient mice. Nat. Commun. 2015;6:5949. [PMC free article: PMC4354252] [PubMed: 25565658]
74. Czech MP, Tencerova M, Pedersen DJ, Aouadi M. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia. 2013;56(5):949–964. [PMC free article: PMC3652374] [PubMed: 23443243]
75. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol. Sci. 2015;36(7):461–470. [PubMed: 26022934]
76. INGALLS AM, DICKIE MM, SNELL GD. Obese, a new mutation in the house mouse. J. Hered. 1950;41(12):317–318. [PubMed: 14824537]
77. Lindström P. The physiology of obese-hyperglycemic mice. ScientificWorldJournal. 2007;7:666–85. [ob/ob mice] [PMC free article: PMC5901356] [PubMed: 17619751]
78. Hausberger FX. Parabiosis and transplantation experiments in hereditary obese mice. Anat Rec 1958;130:313 abstr.
79. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763–770.

[PubMed: 9796811]

80. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. *Science*. 1966;153(3740):1127–1128. [PubMed: 5918576]
81. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. *Diabetologia*. 1978;14(3):141–148. [PubMed: 350680]
82. Harris RB. Loss of body fat in lean parabiotic partners of ob/ob mice. *Am. J. Physiol.* 1997;272(6 Pt 2):R1809–R1815. [PubMed: 9227594]
83. Harris RBS. Parabiosis between db/db and ob/ob or db/+ mice. *Endocrinology*. 1999;140(1):138–145. [PubMed: 9886818]
84. Bahary N, Leibel RL, Joseph L, Friedman JM. Molecular mapping of the mouse db mutation. *Proc. Natl. Acad. Sci. U. S. A.* 1990;87(21):8642–8646. [PMC free article: PMC55013] [PubMed: 1978328]
85. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI. Identification and expression cloning of a leptin receptor, OB-R. *Cell*. 1995;83(7):1263–1271. [PubMed: 8548812]
86. Peelman F, Zabeau L, Moharana K, Savvides SN, Tavernier J. 20 years of leptin: insights into signaling assemblies of the leptin receptor. *J. Endocrinol.* 2014;223(1):T9–23. [PubMed: 25063754]
87. Münzberg H, Morrison CD. Structure, production and signaling of leptin. *Metabolism*. 2015;64(1):13–23. [PMC free article: PMC4267896] [PubMed: 25305050]
88. Wauman J, Tavernier J. Leptin receptor signaling: pathways to leptin resistance. *Front. Biosci. (Landmark Ed.* 2011;16:2771–2793. [PubMed: 21622208]
89. Guo K, McMinn JE, Ludwig T, Yu Y-H, Yang G, Chen L, Loh D, Li C, Chua S, Zhang Y. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. *Endocrinology*. 2007;148(8):3987–3997. [PubMed: 17495001]
90. Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action. *Nat. Med.* 1995;1(12):1311–1314. [PubMed: 7489415]
91. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat. Med.* 1995;1(11):1155–1161. [PubMed: 7584987]
92. Enriori PJ, Evans AE, Sinnayah P, Jobst EE, Tonelli-Lemos L, Billes SK, Glavas MM, Grayson BE, Perello M, Nillni EA, Grove KL, Cowley MA. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. *Cell Metab.* 2007;5(3):181–194. [PubMed: 17339026]
93. Knight ZA, Hannan KS, Greenberg ML, Friedman JM. Hyperleptinemia Is Required for the Development of Leptin Resistance. Stadler K, ed. *PLoS One* 2010;5(6):e11376. [PMC free article: PMC2894068] [PubMed: 20613882]
94. Balland E, Cowley MA. New insights in leptin resistance mechanisms in mice. *Front. Neuroendocrinol.* 2015;39:59–65. [PubMed: 26410445]
95. Friedman J. 20 years of leptin: leptin at 20: an overview. *J. Endocrinol.* 2014;223(1):T1–8. [PubMed: 25121999]
96. Denroche HC, Huynh FK, Kieffer TJ. The role of leptin in glucose homeostasis. *J. Diabetes Investig.* 2012;3(2):115–129. [PMC free article: PMC4020728] [PubMed: 24843554]
97. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell*. 2000;100(2):197–207. [PubMed: 10660043]
98. Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. *Cell Metab.* 2013;18(1):29–42. [PubMed: 23770129]
99. Chen XX, Yang T. Roles of leptin in bone metabolism and bone diseases. *J. Bone Miner. Metab.* 2015;33(5):474–485. [PubMed: 25777984]
100. Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. *Metabolism*. 2015;64(1):35–46. [PubMed: 25497342]

101. Harris RBS. Direct and indirect effects of leptin on adipocyte metabolism. *Biochim. Biophys. Acta.* 2014;1842(3):414–423. [PMC free article: PMC3838442] [PubMed: 23685313]
102. Ghosh S, Mukhopadhyay P, Pandit K, Chowdhury S, Dutta D. Leptin and cancer: pathogenesis and modulation. *Indian J. Endocrinol. Metab.* 2012;16(9):596. [PMC free article: PMC3602989] [PubMed: 23565495]
103. Paik SS, Jang S-M, Jang K-S, Lee KH, Choi D, Jang SJ. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. *Ann. Surg. Oncol.* 2009;16(2):297–303. [PubMed: 19050975]
104. Kim HH, Kim YS, Kang YK, Moon JS. Leptin and peroxisome proliferator-activated receptor γ expression in colorectal adenoma. *World J. Gastroenterol.* 2012;18(6):557–562. [PMC free article: PMC3280402] [PubMed: 22363123]
105. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A. Leptin levels in thyroid cancer. *Asian J. Surg.* 2009;32(4):216–223. [PubMed: 19892624]
106. Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya KS. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. *Endocr. Relat. Cancer.* 2010;17(1):191–202. [PubMed: 20008098]
107. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, Trichopoulos D. Leptin and body mass index in relation to endometrial cancer risk. *Ann. Nutr. Metab.* 2002;46(3–4):147–151. [PubMed: 12169858]
108. Yuan S-SF, Tsai K-B, Chung Y-F, Chan T-F, Yeh Y-T, Tsai L-Y, Su J-H. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. *Gynecol. Oncol.* 2004;92(3):769–775. [PubMed: 14984939]
109. Cymbaluk A, Chudecka-Głaz A, Rzepka-Górska I. Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2008;136(1):74–77. [PubMed: 17007993]
110. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiol. Rev.* 2014;36(1):114–136. [PMC free article: PMC3873844] [PubMed: 24375928]
111. Artac M, Altundag K. Leptin and breast cancer: an overview. *Med. Oncol.* 2012;29(3):1510–1514. [PubMed: 21877194]
112. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J. Biol. Chem.* 1995;270(45):26746–26749. [PubMed: 7592907]
113. Nakano Y, Tobe T, Choi-Miura N-H, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. *J. Biochem.* 1996;120(4):803–812. [PubMed: 8947845]
114. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adiposemost abundant gene transcript 1). *Biochem. Biophys. Res. Commun.* 1996;221(2):286–289. [PubMed: 8619847]
115. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J. Biol. Chem.* 1996;271(18):10697–10703. [PubMed: 8631877]
116. Turer AT, Scherer PE. Adiponectin: Mechanistic insights and clinical implications. *Diabetologia.* 2012;55(9):2319–2326. [PubMed: 22688349]
117. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. *J. Mol. Cell Biol.* 2016;8(2):101–109. [PMC free article: PMC4816150] [PubMed: 26993044]
118. Wang Z V., Scherer PE. Adiponectin, the past two decades. *J. Mol. Cell Biol.* 2016;8(2):93–100. [PMC free article: PMC4816148] [PubMed: 26993047]
119. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadokawa T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. *Endocrinology.* 2005;146(2):790–796. [PubMed: 15528304]
120. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and

- causes weight loss in mice. *Proc. Natl. Acad. Sci.* 2001;98(4):2005–2010. [PMC free article: PMC29372] [PubMed: 11172066]
121. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doepper T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J. Biol. Chem.* 2004;279(13):12152–12162. [PubMed: 14699128]
122. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadokawa T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature.* 2003;423(6941):762–769. [PubMed: 12802337]
123. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao T-S, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. *Proc. Natl. Acad. Sci.* 2004;101(28):10308–10313. [PMC free article: PMC478568] [PubMed: 15210937]
124. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadokawa T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. *Nat. Med.* 2007;13(3):332–339. [PubMed: 17268472]
125. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadokawa T. Adiponectin receptors: a review of their structure, function and how they work. *Best Pract. Res. Clin. Endocrinol. Metab.* 2014;28(1):15–23. [PubMed: 24417942]
126. Chan DW, Lee JMF, Chan PCY, Ng IOL. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. *Int. J. Cancer.* 2008;123(5):1043–1052. [PubMed: 18553387]
127. Vestal DJ, Ranscht B. Glycosyl phosphatidylinositol--anchored T-cadherin mediates calcium-dependent, homophilic cell adhesion. *J. Cell Biol.* 1992;119(2):451–461. [PMC free article: PMC2289661] [PubMed: 1400585]
128. Matsuda K, Fujishima Y, Maeda N, Mori T, Hirata A, Sekimoto R, Tsushima Y, Masuda S, Yamaoka M, Inoue K, Nishizawa H, Kita S, Ranscht B, Funahashi T, Shimomura I. Positive feedback regulation between adiponectin and t-cadherin impacts adiponectin levels in tissue and Plasma of male mice. *Endocrinology.* 2015;156(3):934–946. [PMC free article: PMC4330303] [PubMed: 25514086]
129. Fujishima Y, Maeda N, Matsuda K, Masuda S, Mori T, Fukuda S, Sekimoto R, Yamaoka M, Obata Y, Kita S, Nishizawa H, Funahashi T, Ranscht B, Shimomura I. Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. *FASEB J.* 2017;31(4):1571–1583. [PubMed: 28062540]
130. Denzel MS, Scimia M-C, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. *J. Clin. Invest.* 2010;120(12):4342–4352. [PMC free article: PMC2993592] [PubMed: 21041950]
131. Parker-Duffen JL, Nakamura K, Silver M, Kikuchi R, Tigges U, Yoshida S, Denzel MS, Ranscht B, Walsh K. T-cadherin Is Essential for Adiponectin-mediated Revascularization. *J. Biol. Chem.* 2013;288(34):24886–24897. [PMC free article: PMC3750183] [PubMed: 23824191]
132. Brooks NL, Trent CM, Raetzsch CF, Flurkey K, Boysen G, Perfetti MT, Jeong Y-C, Klebanov S, Patel KB, Khodush VR, Kupper LL, Carling D, Swenberg JA, Harrison DE, Combs TP. Low utilization of circulating glucose after food withdrawal in Snell dwarf mice. *J. Biol. Chem.* 2007;282(48):35069–35077. [PubMed: 17905742]
133. Combs TP, Marliss EB. Adiponectin signaling in the liver. *Rev. Endocr. Metab. Disord.* 2014;15(2):137–147. [PMC free article: PMC4152934] [PubMed: 24297186]
134. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. *Circ. Res.* 2007;100(3):328–341. [PubMed: 17307971]
135. Pirvulescu MM, Gan AM, Stan D, Simion V, Calin M, Butoi E, Manduteanu I. Subendothelial resistin enhances monocyte transmigration in a co-culture of human endothelial and smooth muscle cells by mechanisms involving

- fractalkine, MCP-1 and activation of TLR4 and Gi/o proteins signaling. *Int. J. Biochem. Cell Biol.* 2014;50:29–37. [PubMed: 24508784]
136. Kadowaki T, Yamauchi T, Waki H, Iwabu M, Okada-Iwabu M, Nakamura M. Adiponectin, adiponectin receptors, and epigenetic regulation of adipogenesis. *Cold Spring Harb. Symp. Quant. Biol.* 2011;76(0):257–265. [PubMed: 22492282]
137. Ruscica M, Steffani L, Magni P. Adiponectin interactions in bone and cartilage biology and disease. *Vitamins and hormones.* 2012;90:321–339. In. Vol. [PubMed: 23017721]
138. Dadson K, Liu Y, Sweeney G. Adiponectin action: a combination of endocrine and autocrine/paracrine effects. *Front. Endocrinol. (Lausanne).* 2011;2 [PMC free article: PMC3355882] [PubMed: 22649379] [CrossRef]
139. Santos E, Dos, Pecquery R, Mazancourt P, de, Dieudonné M-N. Adiponectin and Reproduction. *Vitamins and hormones.* 2012;90:187–209. In. Vol. [PubMed: 23017717]
140. Čikos Š. Adiponectin and its receptors in preimplantation embryo development. *Vitamins and hormones.* 2012;90:211–238. In. Vol. [PubMed: 23017718]
141. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *J. Clin. Invest.* 2001;108(12):1875–1881. [PMC free article: PMC209474] [PubMed: 11748271]
142. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to proliferator-activated receptor γ agonists. *J. Biol. Chem.* 2006;281(5):2654–2660. [PubMed: 16326714]
143. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding Y-Y, Russell RG, Lindemann D, Hartley A, Baker GRC, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. *Endocrinology.* 2004;145(1):367–383. [PubMed: 14576179]
144. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T. Pioglitazone ameliorates insulin resistance and diabetes by b adiponectin-dependent and -independent pathways. *J. Biol. Chem.* 2006;281(13):8748–8755. [PubMed: 16431926]
145. Yan W, Zhang H, Liu P, Wang H, Liu J, Gao C, Liu Y, Lian K, Yang L, Sun L, Guo Y, Zhang L, Dong L, Lau WB, Gao E, Gao F, Xiong L, Wang H, Qu Y, Tao L. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1 α signaling contributing to increased vulnerability in diabetic heart. *Basic Res. Cardiol.* 2013;108(3):329. [PubMed: 23460046]
146. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipodystrophy and obesity. *Nat. Med.* 2001;7(8):941–946. [PubMed: 11479627]
147. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. *Eur. J. Endocrinol.* 2005;152(1):113–118. [PubMed: 15762194]
148. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. *World J. Gastroenterol.* 2011;17(23):2801–2811. [PMC free article: PMC3120939] [PubMed: 21734787]
149. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. *Diabetes.* 1982;31(11):957–963. [PubMed: 6757014]
150. Pendergrass M, Bertoldo A, Bonadonna R, Nucci G, Mandarino L, Cobelli C, DeFronzo RA. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. *Am. J. Physiol. Metab.* 2007;292(1):E92–E100. [PubMed: 16896161]
151. Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4

- translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. *Diabetologia*. 2005;48(1):132–139. [PubMed: 15619075]
152. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat. Med.* 2002;8(11):1288–1295. [PubMed: 12368907]
153. Yoon MJ, Lee GY, Chung J-J, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. *Diabetes*. 2006;55(9):2562–2570. [PubMed: 16936205]
154. Wang C, Mao X, Wang L, Liu M, Wetzel MD, Guan K-L, Dong LQ, Liu F. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. *J. Biol. Chem.* 2007;282(11):7991–7996. [PubMed: 17244624]
155. Yano W, Kubota N, Itoh S, Kubota T, Awazawa M, Moroi M, Sugi K, Takamoto I, Ogata H, Tokuyama K, Noda T, Terauchi Y, Ueki K, Kadowaki T. Molecular mechanism of moderate insulin resistance in adiponectin-knockout mice. *Endocr. J.* 2008;55(3):515–522. [PubMed: 18446001]
156. Kandasamy AD, Sung MM, Boisvenue JJ, Barr AJ, Dyck JRB. Adiponectin gene therapy ameliorates high-fat, high-sucrose diet-induced metabolic perturbations in mice. *Nutr. Diabetes*. 2012;2(9):e45–e45. [PMC free article: PMC3461354] [PubMed: 23446660]
157. Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE, Steinberg GR. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese Type 2 diabetics. *J. Clin. Endocrinol. Metab.* 2005;90(6):3665–3672. [PubMed: 15769985]
158. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y., Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler. Thromb. Vasc. Biol.* 2003;23(1):85–89. [PubMed: 12524229]
159. Ding M, Rzucidlo EM, Davey JC, Xie Y, Liu R, Jin Y, Stavola L, Martin KA. Adiponectin in the heart and vascular system. *Vitamins and hormones*. 2012;90:289–319. In. Vol. [PubMed: 23017720]
160. Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R. The cardio-protective signaling and mechanisms of adiponectin. *Am. J. Cardiovasc. Dis.* 2012;2(4):253–266. [PMC free article: PMC3499932] [PubMed: 23173099]
161. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. *Nature*. 2013;503(7477):493–499. [PubMed: 24172895]
162. Choi SR, Lim JH, Kim MY, Kim EN, Kim Y, Choi BS, Kim Y-S, Kim HW, Lim K-M, Kim MJ, Park CW. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. *Metabolism*. 2018 [PubMed: 29462574] [CrossRef]
163. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. *Nature*. 2001;409(6818):307–312. [PubMed: 11201732]
164. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. *J. Biol. Chem.* 2001;276(14):11252–11256. [PubMed: 11278254]
165. Blagoev B, Kratchmarova I, Nielsen MM, Fernandez MM, Voldby J, Andersen JS, Kristiansen K, Pandey A, Mann M. Inhibition of adipocyte differentiation by resistin-like molecule α . *J. Biol. Chem.* 2002;277(44):42011–42016. [PubMed: 12189153]
166. Oliver P, Picó C, Serra F, Palou A. Resistin expression in different adipose tissue depots during rat development. *Mol. Cell. Biochem.* 2003;252(1/2):397–400. [PubMed: 14577616]
167. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. *Diabetes*. 2004;53(7):1671–1679. [PubMed: 15220189]

168. Lefterova MI, Mullican SE, Tomaru T, Qatanani M, Schupp M, Lazar MA. Endoplasmic reticulum stress regulates adipocyte resistin expression. *Diabetes*. 2009;58(8):1879–1886. [PMC free article: PMC2712799] [PubMed: 19491212]
169. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR γ activators. *Biochem. Biophys. Res. Commun.* 2003;300(2):472–476. [PubMed: 12504108]
170. Qatanani M, Szwerdgold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. *J. Clin. Invest.* 2009;119(3):531–539. [PMC free article: PMC2648673] [PubMed: 19188682]
171. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine R V, O’Rahilly S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. *Diabetes*. 2001;50(10):2199–2202. [PubMed: 11574398]
172. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. *J. Cell. Mol. Med.* 2010;14(6B):1419–1431. [PMC free article: PMC3829009] [PubMed: 19754671]
173. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, Lee S, Kim JY, Lee J, Yang HM, Mook-Jung I, Nam KY, Chung J, Lazar MA, Kim HS. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. *Cell Metab.* 2014;19(3):484–497. [PMC free article: PMC3969988] [PubMed: 24606903]
174. Jiang S, Park DW, Tadie J-M, Gregoire M, Deshane J, Pittet JF, Abraham E, Zmijewski JW. Human resistin promotes neutrophil proinflammatory activation and neutrophil extracellular trap formation and increases severity of acute lung injury. *J. Immunol.* 2014;192(10):4795–4803. [PMC free article: PMC4018664] [PubMed: 24719460]
175. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin. *Science*. 2004;303(5661):1195–1198. [PubMed: 14976316]
176. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. *Proc. Natl. Acad. Sci.* 2001;98(2):502–506. [PMC free article: PMC14616] [PubMed: 11209052]
177. Gravleau C, Zaha VG, Mohajer A, Banerjee RR, Dudley-Rucker N, Steppan CM, Rajala MW, Scherer PE, Ahima RS, Lazar MA, Abel ED. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. *J. Biol. Chem.* 2005;280(36):31679–31685. [PubMed: 15983036]
178. Qi Y, Nie Z, Lee Y-S, Singhal NS, Scherer PE, Lazar MA, Ahima RS. Loss of resistin improves glucose homeostasis in leptin deficiency. *Diabetes*. 2006;55(11):3083–3090. [PubMed: 17065346]
179. Singhal NS, Lazar MA, Ahima RS. Central resistin induces hepatic insulin resistance via neuropeptide Y. *J. Neurosci.* 2007;27(47):12924–12932. [PMC free article: PMC6673286] [PubMed: 18032666]
180. Qatanani M, Szwerdgold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. *J. Clin. Invest.* 2009;119(3):531–539. [PMC free article: PMC2648673] [PubMed: 19188682]
181. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. *Trends Endocrinol. Metab.* 2011;22(7):259–265. [PMC free article: PMC3130099] [PubMed: 21497511]
182. Silha J V., Murphy LJ. Serum resistin (FIZZ3) protein is increased in obese humans. *J. Clin. Endocrinol. Metab.* 2004;89(4):1977–1977. [PubMed: 15070974]
183. Degawa-Yamauchi M, Bovenkerk JE, Julian BE, Watson W, Kerr K, Jones R, Zhu Q, Considine R V. Serum resistin (FIZZ3) protein is increased in obese humans. *J. Clin. Endocrinol. Metab.* 2003;88(11):5452–5455. [PubMed: 14602788]
184. BAKER JF, MORALES M, QATANANI M, CUCCHIARA A, NACKOS E, LAZAR MA, TEFF K, VON FELDT JM. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and

- coronary calcification. *J. Rheumatol.* 2011;38(11):2369–2375. [PMC free article: PMC5702914] [PubMed: 21885493]
185. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation.* 2005;111(7):932–939. [PubMed: 15710760]
186. Filková M, Haluzík M, Gay S, Šenolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. *Clin. Immunol.* 2009;133(2):157–170. [PubMed: 19740705]
187. Ding Q, White SP, Ling C, Zhou W. Resistin and cardiovascular disease. *Trends Cardiovasc. Med.* 2011;21(1):20–27. [PubMed: 22498016]
188. Lee SE, Kim H-S. Human resistin in cardiovascular disease. *J. Smooth Muscle Res.* 2012;48(1):27–35. [PubMed: 22504487]
189. Saetang J, Sangkhathat S. Role of innate lymphoid cells in obesity and metabolic disease. *Mol. Med. Rep.* 2018;17(1):1403–1412. (review) [PMC free article: PMC5780078] [PubMed: 29138853]
190. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science.* 1993;259(5091):87–91. [PubMed: 7678183]
191. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* 2003;112(12):1796–1808. [PMC free article: PMC296995] [PubMed: 14679176]
192. Sarjeant K, Stephens JM. Adipogenesis. *Cold Spring Harb. Perspect. Biol.* 2012;4(9):1–19. [PMC free article: PMC3428766] [PubMed: 22952395]
193. Mathieu PS, Loboa EG. Cytoskeletal and focal adhesion influences on mesenchymal stem cell shape, mechanical properties, and differentiation down osteogenic, adipogenic, and chondrogenic pathways. *Tissue Eng. Part B. Rev.* 2012;18(6):436–444. [PMC free article: PMC3495119] [PubMed: 22741572]
194. Poulos SP, Dodson M V, Culver MF, Hausman GJ. The increasingly complex regulation of adipocyte differentiation. *Exp. Biol. Med. (Maywood).* 2016;241(5):449–456. [PMC free article: PMC4950481] [PubMed: 26645953]
195. Engin A. The pathogenesis of obesity-associated adipose tissue inflammation. Advances in experimental medicine and biology. 2017;960:221–245. In: Vol. [PubMed: 28585201]
196. Chen C, Cui Q, Zhang X, Luo X, Liu Y, Zuo J, Peng Y. Long non-coding RNAs regulation in adipogenesis and lipid metabolism: Emerging insights in obesity. *Cell. Signal.* 2018;51:47–58. [PubMed: 30071290]
197. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. *Mol. Cell.* 1999;4(4):611–617. [PubMed: 10549292]
198. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. *Proc. Natl. Acad. Sci. U. S. A.* 2003;100(26):15712–15717. [PMC free article: PMC307633] [PubMed: 14660788]
199. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O’Rahilly S. Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature.* 1999;402(6764):880–883. [PubMed: 10622252]
200. Doney ASF, Fischer B, Leese G, Morris AD, Palmer CNA. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus. *Arterioscler. Thromb. Vasc. Biol.* 2004;24(12):2403–2407. [PubMed: 15486307]
201. Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA, Leff T. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor- γ . *J. Clin. Endocrinol. Metab.* 2007;92(5):1606–1612. [PubMed: 17299075]
202. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPAR γ signaling and metabolism: the good, the bad and the future. *Nat. Med.* 2013;19(5):557–566. [PMC free article: PMC3870016] [PubMed: 23652116]

203. Rangwala SM, Lazar MA. The dawn of the SPPARMs? *Sci. STKE*. 2002;2002(121):pe9. [PubMed: 11867819]
204. Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor γ (PPAR γ) modulation as a strategy for safer therapeutic PPAR γ activation. In: American Journal of Clinical Nutrition.; 2010. doi:10.3945/ajcn.2009.28449E. [PubMed: 19906796] [CrossRef]
205. Wang QA, Zhang F, Jiang L, Ye R, An Y, Shao M, Tao C, Gupta RK, Scherer PE. Peroxisome Proliferator-Activated Receptor γ and Its Role in Adipocyte Homeostasis and Thiazolidinedione-Mediated Insulin Sensitization. *Mol. Cell. Biol.* 2018;38(10) [PMC free article: PMC5954194] [PubMed: 29483301] [CrossRef]
206. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JWR. Structural basis for the activation of PPAR γ by oxidized fatty acids. *Nat. Struct. Mol. Biol.* 2008;15(9):924–931. [PMC free article: PMC2939985] [PubMed: 19172745]
207. Waku T, Shiraki T, Oyama T, Maebara K, Nakamori R, Morikawa K. The nuclear receptor PPAR γ individually responds to serotonin- and fatty acid-metabolites. *EMBO J.* 2010;29(19):3395–3407. [PMC free article: PMC2957204] [PubMed: 20717101]
208. Yanting C, Yang QY, Ma GL, Du M, Harrison JH, Block E. Dose- and type-dependent effects of long-chain fatty acids on adipogenesis and lipogenesis of bovine adipocytes. *J. Dairy Sci.* 2018;101(2):1601–1615. [PubMed: 29153512]
209. Kobayashi T, Fujimori K. Very long-chain-fatty acids enhance adipogenesis through coregulation of Elov13 and PPAR γ in 3T3-L1 cells. *Am. J. Physiol. Metab.* 2012;302(12):E1461–E1471. [PubMed: 22436697]
210. Lee Y-H, Kim S-N, Kwon H-J, Maddipati KR, Granneman JG. Adipogenic role of alternatively activated macrophages in β -adrenergic remodeling of white adipose tissue. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2016;310(1):R55–65. [PMC free article: PMC4796635] [PubMed: 26538237]
211. Baker PRS, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, Long MH, Iles KE, Baker LMS, Branchaud BP, Chen YE, Freeman BA. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. *J. Biol. Chem.* 2005;280(51):42464–75. [PMC free article: PMC2266087] [PubMed: 16227625]
212. Fujimori K, Urade Y. Transcriptional Regulation in Adipogenesis Through PPAR γ -Dependent and -Independent Mechanisms by Prostaglandins. In: Humana Press, New York, NY; 2014:177–196. [PubMed: 24927844]
213. Fujimori K. Prostaglandins as PPAR γ Modulators in Adipogenesis. *PPAR Res.* 2012;2012:527607. [PMC free article: PMC3540890] [PubMed: 23319937]
214. Madsen L, Petersen RK, Kristiansen K. Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. *Biochim. Biophys. Acta - Mol. Basis Dis.* 2005;1740(2):266–286. [PubMed: 15949694]
215. Hamm JK, Park BH, Farmer SR. A role for C/EBP β in regulating peroxisome proliferator-activated receptor γ activity during adipogenesis in 3T3-L1 preadipocytes. *J. Biol. Chem.* 2001;276(21):18464–18471. [PubMed: 11279134]
216. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. *Genes Dev.* 1991;5(9):1538–1552. [PubMed: 1840554]
217. Chen Z, Torrens JI, Anand A, Spiegelman BM, Friedman JM. Krox20 stimulates adipogenesis via C/EBP β -dependent and -independent mechanisms. *Cell Metab.* 2005;1(2):93–106. [PubMed: 16054051]
218. Du C, Ma X, Meruvu S, Hugendubler L, Mueller E. The adipogenic transcriptional cofactor ZNF638 interacts with splicing regulators and influences alternative splicing. *J. Lipid Res.* 2014;55(9):1886–1896. [PMC free article: PMC4617354] [PubMed: 25024404]
219. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. *Immunity*. 2012;36(4):503–514. [PMC free article: PMC3909993] [PubMed: 22520844]
220. Darnell JE. STATs and gene regulation. *Science*. 1997;277(5332):1630–1635. [PubMed: 9287210]
221. Harp JB, Franklin D, Vanderpujje AA, Gimble JM. Differential expression of signal transducers and activators of transcription during human adipogenesis. *Biochem. Biophys. Res. Commun.* 2001;281(4):907–912. [PubMed: 11237746]
222. Stephens JM, Morrison RF, Pilch PF. The expression and regulation of STATs during 3T3-L1 adipocyte

- differentiation. *J. Biol. Chem.* 1996;271(18):10441–10444. [PubMed: 8631837]
223. Hua X, Wu J, Goldstein JL, Brown MS, Hobbs HH. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. *Genomics*. 1995;25(3):667–673. [PubMed: 7759101]
224. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. *J. Clin. Invest.* 1997;99(5):838–845. [PMC free article: PMC507890] [PubMed: 9062340]
225. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. *J. Clin. Invest.* 1998;101(11):2331–2339. [PMC free article: PMC508822] [PubMed: 9616204]
226. Price NL, Holtrup B, Kwei SL, Wabitsch M, Rodeheffer M, Bianchini L, Suárez Y, Fernández-Hernando C. SREBP-1c/MicroRNA 33b genomic loci control adipocyte differentiation. *Mol. Cell. Biol.* 2016;36(7):1180–1193. [PMC free article: PMC4800797] [PubMed: 26830228]
227. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J-I, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. *J. Biol. Chem.* 2002;277(22):19353–19357. [PubMed: 11923308]
228. Åkerblad P, Måansson R, Lagergren A, Westerlund S, Basta B, Lind U, Thelin A, Gisler R, Liberg D, Nelander S, Bamberg K, Sigvardsson M. Gene expression analysis suggests that EBF-1 and PPAR γ 2 induce adipogenesis of NIH-3T3 cells with similar efficiency and kinetics. *Physiol. Genomics*. 2005;23(2):206–216. [PubMed: 16106032]
229. Jimenez MA, Åkerblad P, Sigvardsson M, Rosen ED. Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. *Mol. Cell. Biol.* 2007;27(2):743–757. [PMC free article: PMC1800806] [PubMed: 17060461]
230. Rajakumari S, Wu J, Ishibashi J, Lim H-W, Giang A-H, Won K-J, Reed RR, Seale P. EBF2 determines and maintains brown adipocyte identity. *Cell Metab.* 2013;17(4):562–574. [PMC free article: PMC3622114] [PubMed: 23499423]
231. Stine RR, Shapira SN, Lim H-W, Ishibashi J, Harms M, Won K-J, Seale P. EBF2 promotes the recruitment of beige adipocytes in white adipose tissue. *Mol. Metab.* 2016;5(1):57–65. [PMC free article: PMC4703852] [PubMed: 26844207]
232. Eguchi J, Yan Q-W, Schones DE, Kamal M, Hsu C-H, Zhang MQ, Crawford GE, Rosen ED. Interferon regulatory factors are transcriptional regulators of adipogenesis. *Cell Metab.* 2008;7(1):86–94. [PMC free article: PMC2278019] [PubMed: 18177728]
233. Kumari M, Wang X, Lantier L, Lyubetskaya A, Eguchi J, Kang S, Tenen D, Roh HC, Kong X, Kazak L, Ahmad R, Rosen ED. IRF3 promotes adipose inflammation and insulin resistance and represses browning. *J. Clin. Invest.* 2016;126(8):2839–54. [PMC free article: PMC4966307] [PubMed: 27400129]
234. Kennell JA, MacDougald OA. Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms. *J. Biol. Chem.* 2005;280(25):24004–24010. [PubMed: 15849360]
235. Rao TP, Kühl M. An updated overview on wnt signaling pathways. *Circ. Res.* 2010;106(12):1798–1806. [PubMed: 20576942]
236. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. *Genes Dev.* 1997;11(24):3286–3205. [PubMed: 9407023]
237. Chen N, Wang J. Wnt/ β -catenin signaling and obesity. *Front. Physiol.* 2018;9:792. [PMC free article: PMC6056730] [PubMed: 30065654]
238. Christodoulides C, Scarda A, Granzotto M, Milan G, Dalla Nora E, Keogh J, De Pergola G, Stirling H, Pannacciulli N, Sethi JK, Federspil G, Vidal-Puig A, Farooqi IS, O’Rahilly S, Vettor R. WNT10B mutations in human obesity. *Diabetologia*. 2006;49(4):678–684. [PMC free article: PMC4304000] [PubMed: 16477437]
239. Lagathu C, Christodoulides C, Virtue S, Cawthorn WP, Franzin C, Kimber WA, Nora ED, Campbell M, Medina-

- Gomez G, Cheyette BNR, Vidal-Puig AJ, Sethi JK. Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network. *Diabetes*. 2009;58(3):609–19. [PMC free article: PMC2646059] [PubMed: 19073771]
240. Weiss MJ, Orkin SH. GATA transcription factors: key regulators of hematopoiesis. *Exp. Hematol.* 1995;23(2):99–107. [PubMed: 7828675]
241. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS. Function of GATA transcription factors in preadipocyte-adipocyte transition. *Science*. 2000;290(5489):134–138. [PubMed: 11021798]
242. Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. *Mol. Cell. Biol.* 2005;25(2):706–715. [PMC free article: PMC543409] [PubMed: 15632071]
243. Chen C, Xiang H, Peng Y, Peng J, Jiang S. Mature miR-183, negatively regulated by transcription factor GATA3, promotes 3T3-L1 adipogenesis through inhibition of the canonical Wnt/β-catenin signaling pathway by targeting LRP6. *Cell. Signal.* 2014;26(6):1155–1165. [PubMed: 24556500]
244. Wang L, Di L. Wnt/β-Catenin mediates AICAR effect to increase GATA3 expression and inhibit adipogenesis. *J. Biol. Chem.* 2015;290(32):19458–19468. [PMC free article: PMC4528110] [PubMed: 26109067]
245. de Sá PM, Richard AJ, Hang H, Stephens JM. Transcriptional regulation of adipogenesis. In: Comprehensive Physiology. Vol 7. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2017:635–674. [PubMed: 28333384]
246. Knebel B, Kotzka J, Lehr S, Hartwig S, Avci H, Jacob S, Nitzen U, Schiller M, März W, Hoffmann MM, Seemanova E, Haas J, Muller-Wieland D. A mutation in the c-fos gene associated with congenital generalized lipodystrophy. *Orphanet J. Rare Dis.* 2013;8:11–12. [PMC free article: PMC3750569] [PubMed: 23919306]
247. Gupta RK, Arany Z, Seale P, Mepani RJ, Ye L, Conroe HM, Roby YA, Kulaga H, Reed RR, Spiegelman BM. Transcriptional control of preadipocyte determination by Zfp423. *Nature*. 2010;464(7288):619–623. [PMC free article: PMC2845731] [PubMed: 20200519]
248. Quach JM, Walker EC, Allan E, Solano M, Yokoyama A, Kato S, Sims NA, Gillespie MT, Martin TJ. Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. *J. Biol. Chem.* 2011;286(6):4186–4198. [PMC free article: PMC3039318] [PubMed: 21123171]
249. Shao M, Ishibashi J, Kusminski CM, Wang QA, Hepler C, Vishvanath L, MacPherson KA, Spurgin SB, Sun K, Holland WL, Seale P, Gupta RK. Zfp423 maintains white adipocyte identity through suppression of the beige cell thermogenic gene program. *Cell Metab.* 2016;23(6):1167–1184. [PMC free article: PMC5091077] [PubMed: 27238639]
250. Kang S, Akerblad P, Kiviranta R, Gupta RK, Kajimura S, Griffin MJ, Min J, Baron R, Rosen ED. Regulation of early adipose commitment by Zfp521. *PLoS Biol.* 2012;10(11):1–9. [PMC free article: PMC3507953] [PubMed: 23209378]
251. Correa D, Hesse E, Seriwatanachai D, Kiviranta R, Saito H, Yamana K, Neff L, Atfi A, Coillard L, Sitara D, Maeda Y, Warming S, Jenkins NA, Copeland NG, Horne WC, Lanske B, Baron R. Zfp521 is a target gene and key effector of parathyroid hormone-related peptide signaling in growth plate chondrocytes. *Dev. Cell.* 2010;19(4):533–546. [PMC free article: PMC2958174] [PubMed: 20951345]
252. Zamani N, Brown CW. Emerging roles for the transforming growth factor- β superfamily in regulating adiposity and energy expenditure. *Endocr. Rev.* 2011;32(3):387–403. [PMC free article: PMC3365795] [PubMed: 21173384]
253. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. *Growth Factors*. 1993;9(1):57–71. [PubMed: 8347351]
254. Butterwith SC, Wilkie RS, Clinton M. Treatment of pluripotential C3H 10T1/2 fibroblasts with bone morphogenetic protein-4 induces adipocyte commitment. *Biochem. Soc. Trans.* 1996;24(2):163S. [PubMed: 8736821]
255. Ignatz RA, Massagué J. Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. *Proc. Natl. Acad. Sci. U. S. A.* 1985;82(24):8530–8534. [PMC free article: PMC390950] [PubMed: 3001708]
256. Huang H, Song T-J, Li X, Hu L, He Q, Liu M, Lane MD, Tang Q-Q. BMP signaling pathway is required for

- commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. *Proc. Natl. Acad. Sci. U. S. A.* 2009;106(31):12670–12675. [PMC free article: PMC2722335] [PubMed: 19620713]
257. Hata K, Nishimura R, Ikeda F, Yamashita K, Matsubara T, Nokubi T, Yoneda T. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. *Mol. Biol. Cell.* 2003;14(2):545–55. [PMC free article: PMC149991] [PubMed: 12589053]
258. Margoni A, Fotis L, Papavassiliou AG. The transforming growth factor-beta/bone morphogenetic protein signalling pathway in adipogenesis. *Int. J. Biochem. Cell Biol.* 2012;44(3):475–479. [PubMed: 22226816]
259. Björntorp P. Adipose tissue distribution and function. *Int. J. Obes.* 1991;15 Suppl 2:67–81. [PubMed: 1794941]
260. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. *Int. J. Obes.* 1985;9 Suppl 1:83–92. [PubMed: 4066126]
261. Price TM, O'Brien SN. Determination of estrogen receptor messenger ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in adipocytes and adipose stromal cells by competitive polymerase chain reaction amplification. *J. Clin. Endocrinol. Metab.* 1993;77(4):1041–1045. [PubMed: 8408452]
262. Crandall DL, Busler DE, Novak TJ, Weber R V., Kral JG. Identification of estrogen receptor β RNA in human breast and abdominal subcutaneous adipose tissue. *Biochem. Biophys. Res. Commun.* 1998;248(3):523–526. [PubMed: 9703958]
263. Dieudonné MN, Leneveu MC, Giudicelli Y, Pecquery R. Evidence for functional estrogen receptors α and β in human adipose cells: regional specificities and regulation by estrogens. *Am. J. Physiol. Physiol.* 2004;286(3):C655–C661. [PubMed: 14761887]
264. Jeong S, Yoon M. 17 β -Estradiol inhibition of PPAR γ -induced adipogenesis and adipocyte-specific gene expression. *Acta Pharmacol. Sin.* 2011;32(2):230. [PMC free article: PMC4009938] [PubMed: 21293475]
265. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. *Proc. Natl. Acad. Sci. U. S. A.* 2000;97(23):12729–12734. [PMC free article: PMC18832] [PubMed: 11070086]
266. Jones MEE, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S, Simpson ER. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. *Proc. Natl. Acad. Sci.* 2000;97(23):12735–12740. [PMC free article: PMC18833] [PubMed: 11070087]
267. Pedram A, Razandi M, Blumberg B, Levin ER. Membrane and nuclear estrogen receptor α collaborate to suppress adipogenesis but not triglyceride content. *FASEB J.* 2016;30(1):230–240. [PMC free article: PMC4684544] [PubMed: 26373802]
268. De Pergola G, Xu XF, Yang SM, Giorgino R, Bjorntorp P. Up-regulation of androgen receptor binding in male rat fat pad adipose precursor cells exposed to testosterone: study in a whole cell assay system. *J. Steroid Biochem. Mol. Biol.* 1990;37(4):553–558. [PubMed: 2278839]
269. Dieudonne M-N, Pecquery R, Leneveu M-C, Jaubert A-M, Giudicelli Y. Androgen receptors in cultured rat adipose precursor cells during proliferation and differentiation: regional specificities and regulation by testosterone. *Endocrine.* 1995;3(7):537–541. [PubMed: 21153211]
270. Dieudonne MN, Pecquery R, Boumediene A, Leneveu MC, Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. *Am. J. Physiol.* 1998;274(6 Pt 1):C1645–C1652. [PubMed: 9611130]
271. Blouin K, Veilleux A, Luu-The V, Tchernof A. Androgen metabolism in adipose tissue: Recent advances. *Mol. Cell. Endocrinol.* 2009;301(1–2):97–103. [PubMed: 19022338]
272. Blouin K, Nadeau M, Perreault M, Veilleux A, Drolet R, Marceau P, Mailloux J, Luu-The V, Tchernof A. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. *Clin. Endocrinol. (Oxf).* 2010;72(2):176–188. [PubMed: 19500113]
273. Vegiopoulos A, Herzog S. Glucocorticoids, metabolism and metabolic diseases. *Mol. Cell. Endocrinol.* 2007;275(1–2):43–61. [PubMed: 17624658]
274. Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBP β , C/EBP δ , and glucocorticoids. *Mol.*

- Cell. Biol. 1996;16(8):4128–4136. [PMC free article: PMC231409] [PubMed: 8754811]
275. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN, Rejto PA, Stewart PM. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. *J. Endocrinol.* 2008;197(2):297–307. [PMC free article: PMC2315694] [PubMed: 18434359]
276. Lee M-J, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. *Biochim. Biophys. Acta.* 2014;1842(3):473–81. [PMC free article: PMC3959161] [PubMed: 23735216]
277. Sargis RM, Johnson DN, Choudhury RA, Brady MJ. Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation. *Obesity (Silver Spring)*. 2010;18(7):1283–1288. [PMC free article: PMC3957336] [PubMed: 19927138]
278. Caprio M, Fève B, Clae's A, Viengchareun S, Lombès M, Zennaro M-C. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. *FASEB J.* 2007;21(9):2185–2194. [PubMed: 17384139]
279. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, Fabbri A, Zennaro M-C, Fève B. Antiadipogenic effects of the mineralocorticoid receptor antagonist dospirenone: potential implications for the treatment of metabolic syndrome. *Endocrinology.* 2011;152(1):113–125. [PubMed: 21084448]
280. Lee M-J, Fried SK. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. *Int. J. Obes. (Lond)*. 2014;38(9):1228–1233. [PMC free article: PMC4321810] [PubMed: 24430397]
281. Nimitphong H, Holick MF, Fried SK, Lee M-J. 25-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ promote the differentiation of human subcutaneous preadipocytes. *Makishima M, ed. PLoS One* 2012;7(12):e52171. [PMC free article: PMC3525569] [PubMed: 23272223]
282. Ji S, Doumit ME, Hill RA. Correction: regulation of adipogenesis and key adipogenic gene expression by 1, 25-dihydroxyvitamin D in 3T3-L1 cells. *PLoS One.* 2015;10(7):e0134199. [PMC free article: PMC4514845] [PubMed: 26208276]
283. Ji S, Doumit ME, Hill RA. Regulation of adipogenesis and key adipogenic gene expression by 1, 25-dihydroxyvitamin D in 3T3-L1 cells. *PLoS One.* 2015;10(6):1–29. [PMC free article: PMC4451075] [PubMed: 26030589]
284. Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hollenberg AN. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. *J. Biol. Chem.* 2006;281(16):11205–11213. [PubMed: 16467308]
285. Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D 3 inhibition of adipogenesis in 3T3-L1 cells. *Am. J. Physiol. Metab.* 2006;290(5):E916–E924. [PubMed: 16368784]
286. Kelly KA, Gimble JM. 1,25-Dihydroxy vitamin D 3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. *Endocrinology.* 1998;139(5):2622–2628. [PubMed: 9564879]
287. Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. *J. Cell. Biochem.* 2007;101(1):80–88. [PubMed: 17212358]
288. Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and vitamin D deficiency: a systematic review and meta-analysis. *Obes. Rev.* 2015;16(4):341–349. [PubMed: 25688659]
289. Lotfi-Dizaji L, Mahboob S, Aliashrafi S, Vaghef-Mehraban E, Ebrahimi-Mameghani M, Morovati A. Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: A double-blind placebo-controlled randomized clinical trial. *Clin. Endocrinol. (Oxf).* 2019;90(1):94–101. [PubMed: 30246883]
290. Salehpour A, Hosseinpah F, Shidfar F, Vafa M, Razaghi M, Dehghani S, Hoshiarrad A, Gohari M. A 12-week double-blind randomized clinical trial of vitamin D3supplementation on body fat mass in healthy overweight and obese women. *Nutr. J.* 2012;11(1):78. [PMC free article: PMC3514135] [PubMed: 22998754]
291. Mason C, Xiao L, Imayama I, Duggan C, Wang C-Y, Korde L, McTiernan A. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. *Am. J. Clin. Nutr.* 2014;99(5):1015–1025. [PMC free article: PMC3985208] [PubMed: 24622804]
292. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in

- overweight and obese subjects. *Eur. J. Endocrinol.* 2008;159(6):675–684. [PubMed: 19056900]
293. Mariash CN. Thyroid hormone and the adipocyte. *J. Clin. Endocrinol. Metab.* 2003;88(12):5603–5604. [PubMed: 14671139]
294. Klaus S, Choy L, Champigny O, Cassard-Doulcier AM, Ross S, Spiegelman B, Ricquier D. Characterization of the novel brown adipocyte cell line HIB 1B. Adrenergic pathways involved in regulation of uncoupling protein gene expression. *J. Cell Sci.* 1994;107 (Pt 1):313–319. [PubMed: 8175918]
295. Levacher C, Sztalryd C, Kinebanyan MF, Picon L. Effects of thyroid hormones on adipose tissue development in Sherman and Zucker rats. *Am. J. Physiol.* 1984;246(1 Pt 1):C50–C56. [PubMed: 6364827]
296. Berry DC, Jiang Y, Graff JM. Emerging roles of adipose progenitor cells in tissue development, homeostasis, expansion and thermogenesis. *Trends Endocrinol. Metab.* 2016;27(8):574–585. [PubMed: 27262681]
297. Lee Y-H, Mottillo EP, Granneman JG. Adipose tissue plasticity from WAT to BAT and in between. *Biochim. Biophys. Acta.* 2014;1842(3):358–369. [PMC free article: PMC4435780] [PubMed: 23688783]
298. Jiang Yuwei, Daniel C., Berry WT, Graff JM. Independent stem cell lineages regulate adipose organogenesis and adipose homeostasis. *Cell Rep.* 2014;9(3):1007–1022. [PMC free article: PMC4250841] [PubMed: 25437556]
299. Wang QA, Tao C, Gupta RK, Scherer PE. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. *Nat. Med.* 2013;19(10):1338–1344. [PMC free article: PMC4075943] [PubMed: 23995282]
300. Macotela Y, Emanuelli B, Mori MA, Gesta S, Schulz TJ, Tseng Y-H, Kahn CR. Intrinsic differences in adipocyte precursor cells from different white fat depots. *Diabetes.* 2012;61(7):1691–1699. [PMC free article: PMC3379665] [PubMed: 22596050]
301. Sarjeant K, Stephens JM. Adipogenesis. *Cold Spring Harb. Perspect. Biol.* 2012;4(9):a008417–a008417. [PMC free article: PMC3428766] [PubMed: 22952395]
302. Wang W, Seale P. Control of brown and beige fat development. *Nat. Rev. Mol. Cell Biol.* 2016;17(11):691–702. [PMC free article: PMC5627770] [PubMed: 27552974]
303. Hong KY, Bae H, Park I, Park D-Y, Kim KH, Kubota Y, Cho E-S, Kim H, Adams RH, Yoo O-J, Koh GY. Perilipin+ embryonic preadipocytes actively proliferate along growing vasculatures for adipose expansion. *Development.* 2015;142(15):2623–2632. [PubMed: 26243869]
304. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. PRDM16 controls a brown fat/skeletal muscle switch. *Nature.* 2008;454(7207):961–967. [PMC free article: PMC2583329] [PubMed: 18719582]
305. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Näslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P. Dynamics of fat cell turnover in humans. *Nature.* 2008;453(7196):783–787. [PubMed: 18454136]
306. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. *Cell.* 2008;135(2):240–249. [PubMed: 18835024]
307. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM. White fat progenitor cells reside in the adipose vasculature. *Science.* 2008;322(5901):583–586. [PMC free article: PMC2597101] [PubMed: 18801968]
308. Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Péault B, Rubin JP, Donnenberg AD. Stromal vascular progenitors in adult human adipose tissue. *Cytom. Part A* 2009;9999A(1):NA-NA. [PMC free article: PMC4148047] [PubMed: 19852056]
309. Berry R, Rodeheffer MS. Characterization of the adipocyte cellular lineage in vivo. *Nat. Cell Biol.* 2013;15(3):302–308. [PMC free article: PMC3721064] [PubMed: 23434825]
310. Cawthon WP, Scheller EL, MacDougald OA. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. *J. Lipid Res.* 2012;53(2):227–246. [PMC free article: PMC3269153] [PubMed: 22140268]
311. Majka SM, Fox KE, Psilas JC, Helm KM, Childs CR, Acosta AS, Janssen RC, Friedman JE, Woessner BT, Shade TR, Varella-Garcia M, Klemm DJ. De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific. *Proc. Natl. Acad. Sci.* 2010;107(33):14781–14786. [PMC free article: PMC2930432] [PubMed: 20679227]

312. Majka SM, Miller HL, Sullivan T, Erickson PF, Kong R, Weiser-Evans M, Nemenoff R, Moldovan R, Morandi SA, Davis JA, Klemm DJ. Adipose lineage specification of bone marrow-derived myeloid cells. *Adipocyte*. 2012;1(4):215–229. [PMC free article: PMC3609111] [PubMed: 23700536]
313. Rydén M, Uzunel M, Hård JL, Borgström E, Mold JE, Arner E, Mejhert N, Andersson DP, Widlund Y, Hassan M, Jones C V, Spalding KL, Svahn B-M, Ahmadian A, Frisén J, Bernard S, Mattsson J, Arner P. Transplanted bone marrow-derived cells contribute to human adipogenesis. *Cell Metab*. 2015;22(3):408–417. [PubMed: 26190649]
314. Roldan M, Macias-Gonzalez M, Garcia R, Tinahones FJ, Martin M. Obesity short-circuits stemness gene network in human adipose multipotent stem cells. *FASEB J*. 2011;25(12):4111–4126. [PubMed: 21846837]
315. Tchkonia T, Giorgadze N, Pirtskhalava T, Tchoukalova Y, Karagiannides I, Forse RA, DePonte M, Stevenson M, Guo W, Han J, Waloga G, Lash TL, Jensen MD, Kirkland JL. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. *Am. J. Physiol. Integr. Comp. Physiol.* 2002;282(5):R1286–R1296. [PubMed: 11959668]
316. Baglioni S, Cantini G, Poli G, Francalanci M, Squecco R, Di Franco A, Borgogni E, Frontera S, Nesi G, Liotta F, Lucchese M, Perigli G, Francini F, Forti G, Serio M, Luconi M. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. Gimble JM, ed. *PLoS One* 2012;7(5):e36569. [PMC free article: PMC3344924] [PubMed: 22574183]
317. Mariman ECM, Wang P. Adipocyte extracellular matrix composition, dynamics and role in obesity. *Cell. Mol. Life Sci.* 2010;67(8):1277–1292. [PMC free article: PMC2839497] [PubMed: 20107860]
318. Khan T, Muise ES, Iyengar P, Wang Z V, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. *Mol. Cell. Biol.* 2009;29(6):1575–1591. [PMC free article: PMC2648231] [PubMed: 19114551]
319. Sun K, Tordjman J, Clément K, Scherer PE. Fibrosis and adipose tissue dysfunction. *Cell Metab*. 2013;18(4):470–477. [PMC free article: PMC3795900] [PubMed: 23954640]
320. Lin D, Chun T-H, Kang L. Adipose extracellular matrix remodelling in obesity and insulin resistance. *Biochem. Pharmacol.* 2016;119:8–16. [PMC free article: PMC5061598] [PubMed: 27179976]
321. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. *Endocrinol. Metab. Clin. North Am.* 2008;37(3):753–768. x–xi. [PMC free article: PMC2659415] [PubMed: 18775362]
322. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. *FEBS J*. 2009;276(20):5738–5746. [PMC free article: PMC2896500] [PubMed: 19754873]
323. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *J. Clin. Invest.* 2011;121(6):2094–2101. [PMC free article: PMC3104761] [PubMed: 21633177]
324. Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, Ravussin E, Bray GA, Smith SR. Adipose tissue collagen VI in obesity. *J. Clin. Endocrinol. Metab.* 2009;94(12):5155–5162. [PMC free article: PMC2819828] [PubMed: 19837927]
325. Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, Goncalves Marangoni R, Nicoloro SM, Czech MP, Varga J, Ploug T, An Z, Scherer PE. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. *Nat. Commun.* 2014;5:3485. [PMC free article: PMC4076823] [PubMed: 24647224]
326. Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. *J. Clin. Invest.* 2012;122(11):4243–4256. [PMC free article: PMC3484450] [PubMed: 23041627]
327. Nedergaard J, Bengtsson T, Cannon B. New Powers of Brown Fat: Fighting the Metabolic Syndrome. *Cell Metab*. 2011;13(3):238–240. [PubMed: 21356513]
328. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PLSM, Rinniger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J. Brown adipose tissue activity controls triglyceride clearance. *Nat. Med.* 2011;17(2):200–206. [PubMed: 21258337]
329. Ravussin Y, Xiao C, Gavrilova O, Reitman ML. Effect of Intermittent Cold Exposure on Brown Fat Activation, Obesity, and Energy Homeostasis in Mice. Aguila MB, ed. *PLoS One* 2014;9(1):e85876. [PMC free article: PMC3895006] [PubMed: 24465761]

330. Marlatt KL, Ravussin E. Brown Adipose Tissue: an Update on Recent Findings. *Curr. Obes. Rep.* 2017;6(4):389–396. [PMC free article: PMC5777285] [PubMed: 29101739]
331. Johnson D, Dixon AK, Abrahams PH. The abdominal subcutaneous tissue: computed tomographic, magnetic resonance, and anatomical observations. *Clin. Anat.* 1996;9(1):19–24. [PubMed: 8838275]
332. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. *Am. J. Physiol. Metab.* 2000;278(5):E941–E948. [PubMed: 10780952]
333. Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, Volafova J, Bray GA. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. *Metabolism.* 2001;50(4):425–435. [PubMed: 11288037]
334. Golan R, Shelef I, Rudich A, Gepner Y, Shemesh E, Chassidim Y, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Ben Avraham S, Witkow S, Liberty IF, Tangi-Rosental O, Sarusi B, Stampfer MJ, Shai I. Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes. *Diabetes Care.* 2012;35(3):640–7. [PMC free article: PMC3322677] [PubMed: 22344612]
335. Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. *J. Obes.* 2011;2011:490650. [PMC free article: PMC3042633] [PubMed: 21403826]
336. Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue—link to whole-body phenotypes. *Nat. Rev. Endocrinol.* 2015;11(2):90–100. [PubMed: 25365922]
337. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? *Diabetes.* 2002;51(10):2951–2958. [PubMed: 12351432]
338. Muzumdar R, Allison DB, Huffman DM, Ma X, Atzmon G, Einstein FH, Fishman S, Poduval AD, McVei T, Keith SW, Barzilai N. Visceral adipose tissue modulates mammalian longevity. *Aging Cell.* 2008;7(3):438–440. [PMC free article: PMC2504027] [PubMed: 18363902]
339. Weber R V, Buckley MC, Fried SK, Kral JG. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2000;279(3):R936–R943. [PubMed: 10956251]
340. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. *Cell Metab.* 2008;7(5):410–420. [PMC free article: PMC3204870] [PubMed: 18460332]
341. Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO, Klein S, Abumrad NN. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. *Gastroenterology.* 2010;139(2):448–455. [PMC free article: PMC2910849] [PubMed: 20457158]
342. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. *N. Engl. J. Med.* 2004;350(25):2549–2557. [PubMed: 15201411]
343. Mohammed BS, Cohen S, Reeds D, Young VL, Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. *Obesity (Silver Spring).* 2008;16(12):2648–2651. [PMC free article: PMC2656416] [PubMed: 18820648]
344. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL. Fat tissue, aging, and cellular senescence. *Aging Cell.* 2010;9(5):667–684. [PMC free article: PMC2941545] [PubMed: 20701600]
345. Vohl M-C, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, Hudson TJ, Tchernof A. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. *Obes. Res.* 2004;12(8):1217–1222. [PubMed: 15340102]
346. Gesta S, Blüher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, Boucher J, Lewis C, Kahn CR. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. *Proc. Natl. Acad. Sci. U. S. A.* 2006;103(17):6676–6681. [PMC free article: PMC1458940] [PubMed: 16617105]
347. Karastergiou K, Fried SK, Xie H, Lee M-J, Divoux A, Rosencrantz MA, Chang RJ, Smith SR. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. *J. Clin. Endocrinol. Metab.* 2013;98(1):362–371. [PMC free article: PMC3537084] [PubMed: 23150689]

348. Yamamoto Y, Gesta S, Lee KY, Tran TT, Saadatirad P, Ronald Kahn C. Adipose depots possess unique developmental gene signatures. *Obesity*. 2010;18(5):872–878. [PMC free article: PMC4377838] [PubMed: 20111017]
349. Khan T, Muise ES, Iyengar P, Wang Z V, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. *Mol. Cell. Biol.* 2009;29(6):1575–1591. [PMC free article: PMC2648231] [PubMed: 19114551]
350. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM, Abate N. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. Maedler K, ed. *PLoS One* 2007;2(8):e812. [PMC free article: PMC1950568] [PubMed: 17726542]
351. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. *Science*. 2001;294(5549):2166–2170. [PubMed: 11739957]
352. Rask E, Olsson T, Söderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. *J. Clin. Endocrinol. Metab.* 2001;86(3):1418–1421. [PubMed: 11238541]
353. Sjöström L, Smith U, Krotkiewski M, Björntorp P. Cellularity in different regions of adipose tissue in young men and women. *Metabolism*. 1972;21(12):1143–1153. [PubMed: 4629846]
354. Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. *Diabetes*. 2009;58(4):803–82. [PMC free article: PMC2661589] [PubMed: 19136652]
355. Nishikawa S, Yasoshima A, Doi K, Nakayama H, Uetsuka K. Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. *Exp. Anim.* 2007;56(4):263–272. [PubMed: 17660680]
356. Hwang L-L, Wang C-H, Li T-L, Chang S-D, Lin L-C, Chen C-P, Chen C-T, Liang K-C, Ho I-K, Yang W-S, Chiou L-C. Sex differences in high-fat diet-induced obesity, metabolic alterations and learning, and synaptic plasticity deficits in mice. *Obesity (Silver Spring)*. 2010;18(3):463–469. [PubMed: 19730425]
357. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. *Diabetes*. 1997;46(10):1579–1585. [PubMed: 9313753]
358. Pinnick KE, Neville MJ, Fielding BA, Frayn KN, Karpe F, Hodson L. Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. *Diabetes*. 2012;61(6):1399–1403. [PMC free article: PMC3357300] [PubMed: 22492525]
359. Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2007;293(1):G1–G4. [PMC free article: PMC2887286] [PubMed: 17218471]
360. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. *Pharmacol. Res.* 2006;53(6):482–491. [PubMed: 16644234]
361. Sengenès C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumié A, Lafontan M, Galitzky J. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. *Am. J. Physiol. Integr. Comp. Physiol.* 2002;283(1):R257–R265. [PubMed: 12069952]
362. Kiwaki K, Levine JA. Differential effects of adrenocorticotrophic hormone on human and mouse adipose tissue. *J. Comp. Physiol. B Biochem. Syst. Environ. Physiol.* 2003;173(8):675–678. [PubMed: 12925881]
363. Bousquet-Mélou A, Galitzky J, Lafontan M, Berlan M. Control of lipolysis in intra-abdominal fat cells of nonhuman primates: comparison with humans. *J. Lipid Res.* 1995;36(3):451–461. [PubMed: 7775857]
364. Driskell RR, Jahoda CAB, Chuong C-M, Watt FM, Horsley V. Defining dermal adipose tissue. *Exp. Dermatol.* 2014;23(9):629–631. [PMC free article: PMC4282701] [PubMed: 24841073]
365. Wojciechowicz K, Gledhill K, Ambler CA, Manning CB, Jahoda CAB. Development of the mouse dermal adipose layer occurs independently of subcutaneous adipose tissue and is marked by restricted early expression of FABP4. Schneider MR, ed. *PLoS One* 2013;8(3):e59811. [PMC free article: PMC3608551] [PubMed: 23555789]
366. Kruglikov IL, Scherer PE. Dermal adipocytes: from irrelevance to metabolic targets? *Trends Endocrinol. Metab.* 2016;27(1):1–10. [PMC free article: PMC4698208] [PubMed: 26643658]
367. Alexander CM, Kasza I, Yen C-LE, Reeder SB, Hernando D, Gallo RL, Jahoda CAB, Horsley V, MacDougald OA. Dermal white adipose tissue: a new component of the thermogenic response. *J. Lipid Res.* 2015;56(11):2061–2069. [PMC free article: PMC4617393] [PubMed: 26405076]

368. Matsumura H, Engrav LH, Gibran NS, Yang TM, Grant JH, Yunusov MY, Fang P, Reichenbach DD, Heimbach DM, Isik FF. Cones of skin occur where hypertrophic scar occurs. *Wound Repair Regen.* 2001;9(4):269–277. [PubMed: 11679135]
369. Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM. Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature.* 2013;504(7479):277–281. [PMC free article: PMC3868929] [PubMed: 24336287]
370. Schmidt BA, Horsley V. Intradermal adipocytes mediate fibroblast recruitment during skin wound healing. *Development.* 2013;140(7):1517–1527. [PMC free article: PMC3596993] [PubMed: 23482487]
371. Stepp MA, Gibson HE, Gala PH, Iglesia DDS, Pajooohesh-Ganji A, Pal-Ghosh S, Brown M, Aquino C, Schwartz AM, Goldberger O, Hinkes MT, Bernfield M. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. *J. Cell Sci.* 2002;115(Pt 23):4517–4531. [PubMed: 12414997]
372. Kasza I, Suh Y, Wollny D, Clark RJ, Roopra A, Colman RJ, MacDougald OA, Shedd TA, Nelson DW, Yen M-I, Yen C-LE, Alexander CM. Syndecan-1 is required to maintain intradermal fat and prevent cold stress. Barsh GS, ed. *PLoS Genet.* 2014;10(8):e1004514. [PMC free article: PMC4125098] [PubMed: 25101993]
373. Zhang L -j., Guerrero-Juarez CF, Hata T, Bapat SP, Ramos R, Plikus M V., Gallo RL. Dermal adipocytes protect against invasive *Staphylococcus aureus* skin infection. *Science.* 2015;347(6217):67–71. [PMC free article: PMC4318537] [PubMed: 25554785]
374. Festa E, Fretz J, Berry R, Schmidt B, Rodeheffer M, Horowitz M, Horsley V. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. *Cell.* 2011;146(5):761–771. [PMC free article: PMC3298746] [PubMed: 21884937]
375. Suffee N, Moore-Morris T, Farahmand P, Rücker-Martin C, Dilanian G, Fradet M, Sawaki D, Derumeaux G, LePrince P, Clément K, Dugail I, Puceat M, Hatem SN. Atrial natriuretic peptide regulates adipose tissue accumulation in adult atria. *Proc. Natl. Acad. Sci. U. S. A.* 2017;114(5):E771–E780. [PMC free article: PMC5293064] [PubMed: 28096344]
376. Iacobellis G, Barbaro G. Epicardial adipose tissue feeding and overfeeding the heart. *Nutrition.* 2019;59:1–6. [PubMed: 30415157]
377. Iacobellis G. Epicardial and pericardial fat: close, but very different. *Obesity.* 2012;17(4):625–625. [PubMed: 19322142]
378. Pabon MA, Manocha K, Cheung JW, Lo JC. Linking arrhythmias and adipocytes: insights, mechanisms, and future directions. *Front. Physiol.* 2018;9:1–12. [PMC free article: PMC6290087] [PubMed: 30568603]
379. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: Structure, foetal development and biochemical properties. *Comp. Biochem. Physiol. Part B Comp. Biochem.* 1989;94(2):225–232. [PubMed: 2591189]
380. McAninch EA, Fonseca TL, Poggioli R, Panos AL, Salerno TA, Deng Y, Li Y, Bianco AC, Iacobellis G. Epicardial adipose tissue has a unique transcriptome modified in severe coronary artery disease. *Obesity.* 2015;23(6):1267–1278. [PMC free article: PMC5003780] [PubMed: 25959145]
381. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clément K, Hatem SN. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines. *Eur. Heart J.* 2015;36(13):795–805. [PubMed: 23525094]
382. Sacks HS, Fain JN, Holman B, Cheema P, Chary A, Parks F, Karas J, Optican R, Bahouth SW, Garrett E, Wolf RY, Carter RA, Robbins T, Wolford D, Samaha J. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. *J. Clin. Endocrinol. Metab.* 2009;94(9):3611–3615. [PubMed: 19567523]
383. Greulich S, Maxhera B, Vandenplas G, de Wiza DH, Smiris K, Mueller H, Heinrichs J, Blumensatt M, Cuvelier C, Akhyari P, Ruige JB, Ouwendam, Eckel J. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. *Circulation.* 2012;126(19):2324–2334. [PubMed: 23065384]
384. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson

- AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. *Circulation.* 2003;108(20):2460–2466. [PubMed: 14581396]
385. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. *J. Am. Coll. Cardiol.* 2018;71(20):2360–2372. [PubMed: 29773163]
386. Cetin M, Cakici M, Polat M, Suner A, Zencir C, Ardic I. Relation of epicardial fat thickness with carotid intima-media thickness in patients with type 2 diabetes mellitus. *Int. J. Endocrinol.* 2013;2013:769175. [PMC free article: PMC3665232] [PubMed: 23762053]
387. Iacobellis G, Barbaro G, Gerstein HC. Relationship of epicardial fat thickness and fasting glucose. *Int. J. Cardiol.* 2008;128(3):424–426. [PubMed: 18375002]
388. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia.* 2015;58(3):429–442. [PubMed: 25583541]
389. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve S V., Cho Y, Nadeau-Fredette A-C, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. *JAMA.* 2016;316(3):313. [PubMed: 27434443]
390. Sandouk T, Reda D, Hofmann C. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. *Am. J. Physiol.* 1993;264(6 Pt 1):C1600–8. [PubMed: 8333508]
391. Hallakou S, Doaré L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferré P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. *Diabetes.* 1997;46(9):1393–9. [PubMed: 9287037]
392. Smith SR, de Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. *Metabolism.* 2005;54(1):24–32. [PubMed: 15562376]
393. Chiquette E, Ramirez G, DeFronzo R. A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors. *Arch. Intern. Med.* 2004;164(19):2097. [PubMed: 15505122]
394. McLaughlin TM, Liu T, Yee G, Abbasi F, Lamendola C, Reaven GM, Tsao P, Cushman SW, Sherman A. Pioglitazone Increases the Proportion of Small Cells in Human Abdominal Subcutaneous Adipose Tissue. *Obesity.* 2010;18(5):926–931. [PMC free article: PMC9413023] [PubMed: 19910937]
395. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard B V, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. *Diabetologia.* 1995;38(10):1213–1217. [PubMed: 8690174]
396. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. *Diabetologia.* 2000;43(12):1498–1506. [PubMed: 11151758]
397. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadokawa T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. *J. Clin. Invest.* 1998;101(6):1354–1361. [PMC free article: PMC508690] [PubMed: 9502777]
398. Arner E, Westermark PO, Spalding KL, Britton T, Rydén M, Frisén J, Bernard S, Arner P. Adipocyte turnover: relevance to human adipose tissue morphology. *Diabetes.* 2010;59(1):105–109. [PMC free article: PMC2797910] [PubMed: 19846802]
399. Danforth E. Failure of adipocyte differentiation causes type II diabetes mellitus? *Nat. Genet.* 2000;26(1):13–13. [PubMed: 10973236]
400. Slawik M, Vidal-Puig AJ. Adipose tissue expandability and the metabolic syndrome. *Genes Nutr.* 2007;2(1):41–45. [PMC free article: PMC2474894] [PubMed: 18850138]
401. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids.* 2010;1801(3):338–349. [PubMed: 20056169]

402. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. *Int. J. Obes. Relat. Metab. Disord.* 2004;28 Suppl 4(S4):S12-521. [PubMed: 15592481]
403. McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. *Diabetologia*. 2007;50(8):1707–1715. [PubMed: 17549449]
404. Pasarica M, Xie H, Hymel D, Bray G, Greenway F, Ravussin E, Smith SR. Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetes. *Diabetes Care*. 2009;32(5):900–902. [PMC free article: PMC2671122] [PubMed: 19228873]
405. McLaughlin T, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A, Cushman SW. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. *Obesity (Silver Spring)*. 2014;22(3):673–680. [PMC free article: PMC4344365] [PubMed: 23666871]
406. Michaud A, Laforest S, Pelletier M, Nadeau M, Simard S, Daris M, Lebœuf M, Vidal H, Géloën A, Tchernof A. Abdominal adipocyte populations in women with visceral obesity. *Eur. J. Endocrinol.* 2016;174(2):227–239. [PubMed: 26578637]
407. Kursawe R, Eszlinger M, Narayan D, Liu T, Bazuine M, Cali AMG, D'Adamo E, Shaw M, Pierpont B, Shulman GI, Cushman SW, Sherman A, Caprio S. Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. *Diabetes*. 2010;59(9):2288–2296. [PMC free article: PMC2927952] [PubMed: 20805387]
408. Johannsen DL, Tchoukalova Y, Tam CS, Covington JD, Xie W, Schwarz J-M, Bajpeyi S, Ravussin E. Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the “adipose tissue expandability” hypothesis. *Diabetes Care*. 2014;37(10):2789–2797. [PMC free article: PMC4170127] [PubMed: 25011943]
409. McLaughlin T, Craig C, Liu L-F, Perelman D, Allister C, Spielman D, Cushman SW. Adipose Cell Size and Regional Fat Deposition as Predictors of Metabolic Response to Overfeeding in Insulin-Resistant and Insulin-Sensitive Humans. *Diabetes*. 2016;65(5):1245–1254. [PMC free article: PMC5384627] [PubMed: 26884438]
410. White UA, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E. Association of in vivo adipose tissue cellular kinetics with markers of metabolic health in humans. *J. Clin. Endocrinol. Metab.* 2017;102(7):2171–2178. [PMC free article: PMC5505198] [PubMed: 28323935]
411. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch H-M, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. *Nat. Med.* 2011;17(5):610–617. [PMC free article: PMC3270885] [PubMed: 21499269]
412. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. *Trends Endocrinol. Metab.* 2012;23(8):407–415. [PubMed: 22795937]
413. Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. *J. Clin. Invest.* 2017;127(1):74. [PMC free article: PMC5199684] [PubMed: 28045400]
414. DiSpirito JR, Mathis D. Immunological contributions to adipose tissue homeostasis. *Semin. Immunol.* 2015;27(5):1–17. [PMC free article: PMC4681639] [PubMed: 26616665]
415. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, DeFuria J, Jick Z, Greenberg AS, Obin MS. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes*. 2007;56(12):2910–2918. [PubMed: 17848624]
416. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloria E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J. Lipid Res.* 2005;46(11):2347–2355. [PubMed: 16150820]
417. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. *Am. J. Physiol. Endocrinol. Metab.* 2007;292(1):E166–E174. [PMC free article: PMC3888778] [PubMed: 16926380]
418. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang Z V, Scherer PE. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. *Cell Metab.* 2014;20(1):103–118. [PMC free article: PMC4079756] [PubMed: 24930973]

419. Elks CM, Zhao P, Grant RW, Hang H, Bailey JL, Burk DH, McNulty MA, Mynatt RL, Stephens JM. Loss of oncostatin M signaling in adipocytes induces insulin resistance and adipose tissue inflammation in vivo. *J. Biol. Chem.* 2016;291(33):17066–17076. [PMC free article: PMC5016111] [PubMed: 27325693]
420. Stephens JM, Bailey JL, Hang H, Rittell V, Dietrich MA, Mynatt RL, Elks CM. Adipose tissue dysfunction occurs independently of obesity in adipocyte-specific oncostatin receptor knockout mice. *Obesity*. 2018;26(9):1439–1447. [PMC free article: PMC6146404] [PubMed: 30226002]
421. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. *J. Clin. Invest.* 2019;129(10):3978–3989. [PMC free article: PMC6763224] [PubMed: 31524630]
422. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie M-E, Messier V, Sladek R, Rabasa-Lhoret R. Characterizing the profile of obese patients who are metabolically healthy. *Int. J. Obes.* 2011;35(7):971–981. [PubMed: 20975726]
423. Magkos F. Metabolically healthy obesity: what's in a name? *Am. J. Clin. Nutr.* 2019;110(3):533–539. [PubMed: 31240297]
424. Lackey DE, Burk DH, Ali MR, Mostaedi R, Smith WH, Park J, Scherer PE, Seay SA, McCoin CS, Bonaldo P, Adams SH. Contributions of adipose tissue architectural and tensile properties toward defining healthy and unhealthy obesity. *Am. J. Physiol. Endocrinol. Metab.* 2014;306(3):E233–E246. [PMC free article: PMC3920015] [PubMed: 24302007]
425. Karelis AD, Rabasa-Lhoret R. Can inflammatory status define metabolic health? *Nat. Rev. Endocrinol.* 2013;9(12):694–695. [PubMed: 24126480]
426. Tchernof A, Després J-P. Pathophysiology of human visceral obesity: An update. *Physiol. Rev.* 2013;93(1):359–404. [PubMed: 23303913]
427. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. *Int. J. Obes.* 2010;34(6):949–959. [PubMed: 20065965]
428. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EAH, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? *J. Clin. Endocrinol. Metab.* 2001;86(3):1020–1025. [PubMed: 11238480]
429. Messier V, Karelis AD, Prud'homme D, Primeau V, Brochu M, Rabasa-Lhoret R. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. *Obesity*. 2010;18(5):911–917. [PubMed: 19851302]
430. Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M. Insulin-sensitive obesity. *Am. J. Physiol. Metab.* 2010;299(3):E506–E515. [PubMed: 20570822]
431. O'Connell J, Lynch L, Cawood TJ, Kwasnik A, Nolan N, Geoghegan J, McCormick A, O'Farrelly C, O'Shea D. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. *PLoS One.* 2010;5(4):e9997. [PMC free article: PMC2848665] [PubMed: 20376319]
432. Shulman GI. Cellular mechanisms of insulin resistance. *J. Clin. Invest.* 2000;106(2):171–176. [PMC free article: PMC314317] [PubMed: 10903330]
433. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal Muscle Lipid Content and Insulin Resistance: Evidence for a Paradox in Endurance-Trained Athletes. *J. Clin. Endocrinol. Metab.* 2001;86(12):5755–5761. [PubMed: 11739435]
434. Etgen GJ, Jensen J, Wilson CM, Hunt DG, Cushman SW, Ivy JL. Exercise training reverses insulin resistance in muscle by enhanced recruitment of GLUT-4 to the cell surface. *Am. J. Physiol.* 1997;272(5 Pt 1):E864–9. [PubMed: 9176187]
435. Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J. Clin. Endocrinol. Metab.* 2002;87(7):3023–3028. [PubMed: 12107194]
436. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritzsche A, Häring H-U. Identification and characterization of metabolically benign obesity in humans. *Arch. Intern. Med.* 2008;168(15):1609. [PubMed: 18695074]

437. Ogorodnikova AD, Khan UI, McGinn AP, Zeb I, Budoff MJ, Harman SM, Miller VM, Brinton EA, Manson JE, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Ectopic fat and adipokines in metabolically benign overweight/obese women: the kronos early estrogen prevention study. *Obesity (Silver Spring)*. 2013;21(8):1726–1733. [PMC free article: PMC3748250] [PubMed: 23670850]
438. Shin M-J, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. *Int. J. Obes.* 2006;30(10):1529–1534. [PubMed: 16552406]
439. Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM, Visser M, Houston DK, Nicklas BJ, Tylavsky FA, Satterfield S, Goodpaster BH, Ferrucci L, Harris TB, Health ABC Study. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. *Obesity (Silver Spring)*. 2010;18(12):2354–2361. [PMC free article: PMC3095947] [PubMed: 20395951]
440. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? *J. Clin. Endocrinol. Metab.* 2013;98(10):E1610–E1619. [PubMed: 23979951]
441. Wildman RP, Kaplan R, Manson JE, Rajkovic A, Connelly SA, Mackey RH, Tinker LF, Curb JD, Eaton CB, Wassertheil-Smoller S. Body size phenotypes and inflammation in the women's health initiative observational study. *Obesity*. 2011;19(7):1482–1491. [PMC free article: PMC3124587] [PubMed: 21233809]
442. Blüher M. The distinction of metabolically "healthy" from "unhealthy" obese individuals. *Curr. Opin. Lipidol.* 2010;21(1):38–43. [PubMed: 19915462]
443. van Beek L, Lips MA, Visser A, Pijl H, Ioan-Facsinay A, Toes R, Berends FJ, Willems van Dijk K, Koning F, van Harmelen V. Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. *Metabolism*. 2014;63(4):492–501. [PubMed: 24467914]
444. Xu XJ, Gauthier M-S, Hess DT, Apovian CM, Cacicedo JM, Gokce N, Farb M, Valentine RJ, Ruderman NB. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. *J. Lipid Res.* 2012;53(4):792–801. [PMC free article: PMC3307656] [PubMed: 22323564]
445. Hardy OT, Perugini RA, Nicoloro SM, Gallagher-Dorval K, Puri V, Straubhaar J, Czech MP. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. *Surg. Obes. Relat. Dis.* 2011;7(1):60–67. [PMC free article: PMC2980798] [PubMed: 20678967]
446. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, Adams RJ. North West Adelaide Health Study Team on behalf of the NWAHS. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. *Diabetes Care*. 2013;36(8):2388–2394. [PMC free article: PMC3714523] [PubMed: 23491523]
447. Chang Y, Ryu S, Suh B-S, Yun KE, Kim C-W, Cho S-I. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. *Int. J. Obes.* 2012;36(9):1187–1194. [PubMed: 22158268]
448. Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E, García-Fuentes E, Almaraz MC, Colomo N, Esteva de Antonio I, de Adana MSR, Chaves FJ, Morcillo S, Valdés S, Rojo-Martínez G. Metabolically healthy but obese, a matter of time? Findings from the prospective pizarra study. *J. Clin. Endocrinol. Metab.* 2013;98(6):2318–2325. [PubMed: 23559087]
449. Samocha-Bonet D, Dixit VD, Kahn CR, Leibel RL, Lin X, Nieuwdorp M, Pietiläinen KH, Rabasa-Lhoret R, Roden M, Scherer PE, Klein S, Ravussin E. Metabolically healthy and unhealthy obese--the 2013 Stock Conference report. *Obes. Rev.* 2014;15(9):697–708. [PMC free article: PMC4519075] [PubMed: 25059108]
450. Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. *Medicine (Baltimore)*. 2017;96(47):e8838. [PMC free article: PMC5708991] [PubMed: 29381992]
451. Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, Vaidya D. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. *J. Am. Coll. Cardiol.* 2018;71(17):1857–1865. [PMC free article: PMC6002856] [PubMed: 29699611]
452. Akinci B, Sahinoz M, Oral E. Lipodystrophy Syndromes: Presentation and Treatment. MDText.com, Inc.; 2000.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29989768>. Accessed March 20, 2020. [PubMed: 29989768]

453. Garg A. Lipodystrophies: genetic and acquired body fat disorders. *J. Clin. Endocrinol. Metab.* 2011;96(11):3313–3325. [PMC free article: PMC7673254] [PubMed: 21865368]
454. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. *Trends Pharmacol. Sci.* 2005;26(2):88–93. [PubMed: 15681026]
455. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care? *Diabetes Care.* 2013;36(8):2142–2145. [PMC free article: PMC3714480] [PubMed: 23881965]
456. Huang-Doran I, Sleigh A, Rochford JJ, O’Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. *J. Endocrinol.* 2010;207(3):245–255. [PubMed: 20870709]
457. Savage DB. Mouse models of inherited lipodystrophy. *Dis. Model. Mech.* 2009;2(11–12):554–562. [PubMed: 19892886]
458. Vernoche C, Damilano F, Mourier A, Bezy O, Mori MA, Smyth G, Rosenzweig A, Larsson N-G, Kahn CR. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. *FASEB J.* 2014;28(10):4408–4419. [PMC free article: PMC4202105] [PubMed: 25005176]
459. Oral E, Chan J. Rationale for leptin-replacement therapy for severe lipodystrophy. *Endocr. Pract.* 2010;16(2):324–333. [PubMed: 20061299]
460. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. *J. Clin. Endocrinol. Metab.* 2004;89(9):4258–4263. [PMC free article: PMC2266890] [PubMed: 15356018]
461. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. *Genes Dev.* 1998;12(20):3168–3181. [PMC free article: PMC317213] [PubMed: 9784492]
462. Reitman ML, Mason MM, Moitra J, Gavrilova O, Marcus-Samuels B, Eckhaus M, Vinson C. Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. *Ann. N. Y. Acad. Sci.* 1999;892:289–296. [PubMed: 10842669]
463. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *J. Clin. Invest.* 2000;105(3):271–278. [PMC free article: PMC377444] [PubMed: 10675352]
464. Zhang Z, Turer E, Li X, Zhan X, Choi M, Tang M, Press A, Smith SR, Divoux A, Moresco EMY, Beutler B. Insulin resistance and diabetes caused by genetic or diet-induced KBTBD2 deficiency in mice. *Proc. Natl. Acad. Sci. U. S. A.* 2016;113(42):E6418–E6426. [PMC free article: PMC5081616] [PubMed: 27708159]
465. Colombo C, Cutson JJ, Yamauchi T, Vinson C, Kadowaki T, Gavrilova O, Reitman ML. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. *Diabetes.* 2002;51(9):2727–2733. [PubMed: 12196465]
466. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. *Nature.* 1999;401(6748):73–76. [PubMed: 10485707]
467. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. *N. Engl. J. Med.* 2002;346(8):570–578. [PubMed: 11856796]
468. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum Adiponectin and Leptin Levels in Patients with Lipodystrophies. *J. Clin. Endocrinol. Metab.* 2002;87(5):2395–2395. [PubMed: 11994394]
469. Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. *Metabolism.* 2019;96:66–82. [PubMed: 31071311]
470. Akinci B, Onay H, Demir T, Ozen S, Kayserili H, Akinci G, Nur B, Tuysuz B, Nuri Ozbek M, Gungor A, Yildirim Simsir I, Altay C, Demir L, Simsek E, Atmaca M, Topaloglu H, Bilen H, Atmaca H, Atik T, Cavdar U, Altunoglu U, Aslanger A, Mihci E, Secil M, Saygili F, Comlekci A, Garg A. Natural history of congenital

- generalized lipodystrophy: A nationwide study from turkey. *J. Clin. Endocrinol. Metab.* 2016;101(7):2759–2767. [PMC free article: PMC7958923] [PubMed: 27144933]
471. Akinci B, Onay H, Demir T, Savas-Erdeve S, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. *Metabolism.* 2017;72:109–119. [PubMed: 28641778]
472. Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho M de FP, Lima DN. de Melo Campos JTA, Ferreira LC, Freire Neto FP, Mendes-Aguiar C de O, Jeronimo SMB. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. *PLoS One.* 2018;13(6):e0199052. [PMC free article: PMC5993255] [PubMed: 29883474]
473. Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. *Diabetes, Obes. Metab.* 2008;10(12):1275–1276. [PubMed: 19040647]
474. Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. *Semin. Reprod. Med.* 2002;20(2):139–144. [PubMed: 12087499]
475. Kawa JF, Summer R, Kallen CB. Direct effects of leptin and adiponectin on peripheral reproductive tissues: a critical review. *Mol. Hum. Reprod.* 2015;21(8):617–632. [PMC free article: PMC4518135] [PubMed: 25964237]
476. Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: a review. *Fertil. Steril.* 2002;77(3):433–444. [PubMed: 11872190]
477. O’Rahilly S, Farooqi IS, Yeo GSH, Challis BG. Minireview: human obesity—lessons from monogenic disorders. *Endocrinology.* 2003;144(9):3757–3764. [PubMed: 12933645]
478. Hausman GJ, Barb CR. Adipose tissue and the reproductive axis: biological aspects. In: *Adipose Tissue Development.* Vol 19. Basel: KARGER; 2010:31–44. [PubMed: 20551666]
479. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, Clifton DK, Steiner RA. Leptin is a metabolic signal to the reproductive system. *Endocrinology.* 1996;137(7):3144–3147. [PubMed: 8770941]
480. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. Leptin concentrations in relation to body mass index and the tumor necrosis factor- α system in humans 1. *J. Clin. Endocrinol. Metab.* 1997;82(10):3408–3413. [PubMed: 9329377]
481. Apter D. The role of leptin in female adolescence. *Ann. N. Y. Acad. Sci.* 2003;997(1):64–76. [PubMed: 14644811]
482. Wen J-P, Lv W-S, Yang J, Nie A-F, Cheng X-B, Yang Y, Ge Y, Li X-Y, Ning G. Globular adiponectin inhibits GnRH secretion from GT1-7 hypothalamic GnRH neurons by induction of hyperpolarization of membrane potential. *Biochem. Biophys. Res. Commun.* 2008;371(4):756–761. [PubMed: 18466765]
483. Kiezon M, Smolinska N, Maleszka A, Dobrzyn K, Szyszko K, Kaminski T. Adiponectin expression in the porcine pituitary during the estrous cycle and its effect on LH and FSH secretion. *Am. J. Physiol. Metab.* 2014;307(11):E1038–E1046. [PubMed: 25315693]
484. Chabrolle C, Tosca L, Dupont J. Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadotrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. *Reproduction.* 2007;133(4):719–731. [PubMed: 17504916]
485. Tworoger SS, Mantzoros C, Hankinson SE. Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels*. *Obesity.* 2007;15(9):2217–2224. [PubMed: 17890489]
486. Henson MC, Castracane VD. Leptin in pregnancy: an update. *Biol. Reprod.* 2006;74(2):218–229. [PubMed: 16267210]
487. Stein TP, Scholl TO, Schluter MD, Schroeder CM. Plasma leptin influences gestational weight gain and postpartum weight retention. *Am. J. Clin. Nutr.* 1998;68(6):1236–1240. [PubMed: 9846852]
488. Sámano R, Martínez-Rojano H, Chico-Barba G, Godínez-Martínez E, Sánchez-Jiménez B, Montiel-Ojeda D, Tolentino M. Serum concentration of leptin in pregnant adolescents correlated with gestational weight gain, postpartum weight retention and newborn weight/length. *Nutrients.* 2017;9(10):1–16. [PMC free article: PMC5691684] [PubMed: 28953229]
489. Schubring C, Englaro P, Siebler T, Blum WF, Demirakca T, Kratzsch J, Kiess W. Longitudinal analysis of

- maternal serum leptin levels during pregnancy, at birth and up to six weeks after birth: relation to body massindex, skinfolds, sex steroids and umbilical cord blood leptin levels. *Horm. Res. Paediatr.* 1998;50(5):276–283. [PubMed: 9873196]
490. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, Espinoza J, Yoon BH, Hassan SS. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. *J. Perinat. Med.* 2007;35(6):522–531. [PMC free article: PMC2410085] [PubMed: 17919116]
491. Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J. Clin. Endocrinol. Metab.* 2004;89(5):2306–2311. [PubMed: 15126557]
492. Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, Isler CM, Newton ER, Dohm GL, DeVente JE. Gestational diabetes is associated with depressed adiponectin levels. *J. Soc. Gynecol. Investig.* 2005;12(1):41–45. [PubMed: 15629670]
493. Lekva T, Roland MCP, Michelsen AE, Friis CM, Aukrust P, Bollerslev J, Henriksen T, Ueland T. Large reduction in adiponectin during pregnancy is associated with large-for-gestational-age newborns. *J. Clin. Endocrinol. Metab.* 2017;102(7):2552–2559. [PubMed: 28460045]
494. Michalakis KG, Segars JH. The role of adiponectin in reproduction: from polycystic ovary syndrome to assisted reproduction. *Fertil. Steril.* 2010;94(6):1949–1957. [PMC free article: PMC3127205] [PubMed: 20561616]
495. Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. *Metabolism.* 2005;54(2):255–263. [PubMed: 15690321]
496. Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction. *Obstet. Gynecol.* 2012;119(2 Pt 2):452–455. [PMC free article: PMC3470464] [PubMed: 22270436]
497. Ahima RS. Body fat, leptin, and hypothalamic amenorrhea. *N. Engl. J. Med.* 2004;351(10):959–962. [PubMed: 15342803]
498. Mathew H, Castracane VD, Mantzoros C. Adipose tissue and reproductive health. *Metabolism.* 2018;86:18–32. [PubMed: 29155136]
499. Ruscica M, Macchi C, Gandini S, Morlotti B, Erzegovesi S, Bellodi L, Magni P. Free and bound plasma leptin in anorexia nervosa patients during a refeeding program. *Endocrine.* 2016;51(2):380–383. [PubMed: 25863491]
500. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim S-Y, Hamnvik O-PR, Koniaris A. Leptin in human physiology and pathophysiology. *Am. J. Physiol. Endocrinol. Metab.* 2011;301(4):E567–E584. [PMC free article: PMC3191548] [PubMed: 21791620]
501. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant Human Leptin in Women with Hypothalamic Amenorrhea. *N. Engl. J. Med.* 2004;351(10):987–997. [PubMed: 15342807]
502. Lambrinoudaki I, Papadimitriou D. Pathophysiology of bone loss in the female athlete. *Ann. N. Y. Acad. Sci.* 2010;1205(1):45–50. [PubMed: 20840252]
503. Mantzoros CS, Georgiadis EI. Body mass and physical activity are important predictors of serum androgen concentrations in young healthy men. *Epidemiology.* 1995;6(4):432–5. [PubMed: 7548356]
504. Kelly DM, Jones TH. Testosterone and obesity. *Obes. Rev.* 2015;16(7):581–606. [PubMed: 25982085]
505. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. *Med. Hypotheses.* 1999;52(1):49–51. [PubMed: 10342671]
506. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadimas I, Panidis D. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. *Hum. Reprod. Update.* 2009;15(3):297–307. [PubMed: 19261627]
507. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat. Rev. Cancer.* 2004;4(8):579–591. [PubMed: 15286738]
508. Nagaraju GP, Rajitha B, Aliya S, Kotipatrungi RP, Madanraj AS, Hammond A, Park D, Chigurupati S, Alam A, Pattnaik S. The role of adiponectin in obesity-associated female-specific carcinogenesis. *Cytokine Growth Factor Rev.* 2016;31:37–48. [PubMed: 27079372]

509. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanier E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. *J. Clin. Endocrinol. Metab.* 2004;89(3):1102–1107. [PubMed: 15001594]
510. Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus M V. Anatomical, physiological, and functional diversity of adipose tissue. *Cell Metab.* 2018;27(1):68–83. [PMC free article: PMC6050204] [PubMed: 29320711]
511. Blaszkiewicz M, Willows JW, Johnson CP, Townsend KL, Blaszkiewicz M, Willows JW, Johnson CP, Townsend KL. The importance of peripheral nerves in adipose tissue for the regulation of energy balance. *Biology (Basel).* 2019;8(1):10. [PMC free article: PMC6466238] [PubMed: 30759876]
512. Stanford KI, Middelbeek RJW, Townsend KL, Lee M-Y, Takahashi H, So K, Hitchcox KM, Markan KR, Hellbach K, Hirshman MF, Tseng Y-H, Goodyear LJ. A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. *Diabetes.* 2015;64(6):2002–2014. [PMC free article: PMC4439563] [PubMed: 25605808]
513. Stanford KI, Lynes MD, Takahashi H, Baer LA, Arts PJ, May FJ, Lehnig AC, Middelbeek RJW, Richard JJ, So K, Chen EY, Gao F, Narain NR, Distefano G, Shettigar VK, Hirshman MF, Ziolo MT, Kiebish MA, Tseng Y-H, Coen PM, Goodyear LJ. 12,13-diHOME: an exercise-induced lipokine that increases skeletal muscle fatty acid uptake. *Cell Metab.* 2018;27(5):1111–1120. [PMC free article: PMC5935136] [PubMed: 29719226]
514. Flaherty SE, Grijalva A, Xu X, Ables E, Nomani A, Ferrante AW. A lipase-independent pathway of lipid release and immune modulation by adipocytes. *Science.* 2019;363(6430):989–993. [PMC free article: PMC6579605] [PubMed: 30819964]
515. Crewe C, Joffin N, Rutkowski JM, Kim M, Zhang F, Towler DA, Gordillo R, Scherer PE. An endothelial-to-adipocyte extracellular vesicle axis governed by metabolic state. *Cell.* 2018;175(3):695–708. [PMC free article: PMC6195477] [PubMed: 30293865]

Copyright © 2000-2022, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at <http://creativecommons.org/licenses/by-nd/2.0/>.

Bookshelf ID: NBK555602 PMID: 32255578